{\rtf1\ansi\ansicpg1252\uc1 \deff28\deflang1033\deflangfe1033\deftab360{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f4\froman\fcharset0\fprq2{\*\panose 00000000000000000000}Times;}{\f14\fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f28\fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f29\fswiss\fcharset128\fprq2{\*\panose 00000000000000000000}@Arial Unicode MS;}{\f128\froman\fcharset238\fprq2 Times New Roman CE;}{\f129\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f131\froman\fcharset161\fprq2 Times New Roman Greek;}{\f132\froman\fcharset162\fprq2 Times New Roman Tur;}{\f133\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f134\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f135\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f144\fmodern\fcharset238\fprq1 Courier New CE;}{\f145\fmodern\fcharset204\fprq1 Courier New Cyr;}{\f147\fmodern\fcharset161\fprq1 Courier New Greek;}{\f148\fmodern\fcharset162\fprq1 Courier New Tur;}{\f149\fmodern\fcharset177\fprq1 Courier New (Hebrew);}{\f150\fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f151\fmodern\fcharset186\fprq1 Courier New Baltic;}{\f354\fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f352\fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f353\fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f355\fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f356\fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f357\fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f358\fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f359\fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red221\green221\blue221;\red153\green153\blue153;\red222\green222\blue233;\red102\green51\blue204;\red150\green150\blue150;\red254\green248\blue217;}{\info{\title Factiva RTF Display Format}{\author Factiva, from Dow Jones.}{\operator Factiva, from Dow Jones.}{\creatim\yr2005\mo2\dy5\hr12\min00}{\revtim\yr2005\mo2\dy5\hr12\min00}{\version2}{\edmins4}{\nofpages1}{\nofwords16}{\nofchars93}{\*\company Factiva, from Dow Jones.}{\nofcharsws114}{\vern8279}} \paperh15840\paperw12240\widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1800\dgvorigin1440\dghshow1\dgvshow1\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule \fet0\sectd \titlepg \linex0\endnhere\pgbrdropt32\sectlinegrid360\sectdefaultcl\margr1440\margl1440 {\headerf\pard\plain \s21\qc \li-1008\ri-1008\widctlpar\tqc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin-1008\lin-1008\itap0 \fs20\lang1033\langfe1033\loch\af28\hich\af28\dbch\af28\cgrid\langnp1033\langfenp1033 {\f0\fs16\qr\ri0{\*\shppict{\pict\jpegblip\picw117\pich70\picscaley100\picscalex100\picwgoal1755\pichgoal1050
FF
D8FFE1001845786966000049492A00080000000000000000000000FFEC00114475636B79000100040000003C0000FFE1031F687474703A2F2F6E732E61646F62
652E636F6D2F7861702F312E302F003C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A7265537A4E54637A6B6339
64223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F626520584D5020436F7265
20352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C7264663A52444620786D6C6E
733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E203C7264663A446573637269
7074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F22
20786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D
6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E7449443D22786D702E646964
3A41323833444137413541454331314535423730414642454331423332443443442220786D704D4D3A496E7374616E636549443D22786D702E6969643A413238
33444137393541454331314535423730414642454331423332443443442220786D703A43726561746F72546F6F6C3D2241646F62652050686F746F73686F7020
43432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D2243353942433442
41323033324339414238413541444443363033343137334630222073745265663A646F63756D656E7449443D2243353942433442413230333243394142384135
41444443363033343137334630222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F7870
61636B657420656E643D2272223F3EFFEE000E41646F62650064C000000001FFDB0084000604040405040605050609060506090B080606080B0C0A0A0B0A0A0C
100C0C0C0C0C0C100C0E0F100F0E0C1313141413131C1B1B1B1C1F1F1F1F1F1F1F1F1F1F010707070D0C0D181010181A1511151A1F1F1F1F1F1F1F1F1F1F1F1F
1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1FFFC00011080046007503011100021101031101FFC4007C00010003
01010100000000000000000000000306070405080101010101000000000000000000000000000102031000010303030203070403010000000000020001030405
061112072113314122513223141516086142331752433618110101010101000203010101000000000000010211213112415103226113FFDA000C030100021103
11003F00FAA501010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101
01061F985B723C9F9CA6C669328BAD86DF15942B986DF532C62F20CCC0FF000C4C47AB1F57FD1749E471D4B75CEBB78BAEF9759793EFBC757CBCCB7FA4A3A20B
8505C2AB579C59DE26702277227D5A7F327F77A69AA9AE73A62D9AE556305B4E7DCA768BBE5D2E6B73B219554D05B2DB412C915344D10898EF0030DCDEB61F6F
4D5DDF556F278CE65D7BD1F36CCB26FC6BACBF0DCAA69AFD67A91092BE9253A79658E290189CCA270FF54DEAF6EDD539268FB5B8EA3CBF9AEE1167D814D49592
C7678E8E8EAEFD1C6643097D4C4589A7067DA5DA8DD8877783BF45667CA6BFA7B176E31BCDE6FBCABC8359357D4CB67B64F15B68684A590A980E377090A389DF
6096B4FABBB37EEFD56753C8DE2DBAAD6161D593E417ABCC5F9218CDA22AFA88ED551679659EDE329B539C8DF37A19C4CFB08BD03D5DBC996E4FF2E56DFBC576
829B32E4CE42CC69DF2BB8E3D69C66ABE9F47496B90A1DE4C7206F37021DDD61727D757EBA368CCAF92333BAB7DF8498565D969F1EF26D96EB7396B6E787C771
A5A3BCB11054176E19C44F7B3EFDC2706E12D7775F1E8964EC33ABCB3F4AD71BF2C647271E64B8FE415D54D7BFA3575D31CBACD29BD44D13432396C99DF7B944
60E40FAEBD1DBA6D5759F59C6EF2CAECCBB2ACA20FC68C6EF105E2BA2BB4F5318CF710A9986A4C5CAA3563998B7937A5BC5FC924FF004BAD5FA45838ABEDAAAC
C602B57275E3279E9A29653B4561D53C060E1DB723697417D8523137EAA6BE3E1AC73BF3D52EFD94DCABF9072AB76599D5D70CA8A4A93871FA6A6EFC74650B11
768E4ECBB7420602DCFA6BAF8F92B279E462EBDBDBC6C5BF28FEA1DDF75DBFEADF2FFF005BAB7CAF67B9FCDBBDDDDD9F4EEFF2EAB1F975F7EBF2AE66566E51B6
72F4997E298EC77AA596D216F779AAA9E0162797B85D0E58CF56DADE5A755659CE56753535D91DDC6584E71F7D5E7903348E9E86E972A61A1A6B5D29B4831422
F1BBB910918EBF0474D09FCFC13567391719BDED5631CC6F9C38EA8EEB8D63362A3BE59EA2A25A8B6DCCEA6288A2EE8B036F8E492322D0405DC74F1D7ABB2B6C
ACC9ACF916EC1F8A6AEC5C395F8757184D71BA53D5BD4F6DF58C26A98DC00449F4D76330F5F6A975EF5BCE399E33DC33813286E33CBE8F20A3ED649730863B54
273432930D00B490334A06602D21FC3EA5D19BD8B577EB9E7F95FADEFCB45E00C1EFF89E1F57164503C17BB857CB5754252473168E2003B8E32317D76B978F9A
C6EF6BA7F2CD93D5AB3F87349318A9FB3278A0BFC6E274CD30810482CFEB8FE23388B90F83BF9FB149CFCB5AEF3C6738962DCA17CE57B7E6D995A69EC91DA2DC
5451C314F14EF399B48CE4CD11CBB7ACE4EFABB79375F15AB67391CF39D5D76A27C6796706CEB26BAE2166A5C8AD193CFF003A612D4474F24136E33767EE1C7D
374A5E1AEADA783A7659E9CD66DE7E5D387F19E6141C7F9EC978088F2BCCE2AE98A82031ED84D3C32B471EF72EDB3949317EEDACDA754BA9D8671797F75E25EB
83EFD75E16B0DBDA95A9736B0C530C50B4B133C91CF29F7698A51378F4303D5BD5A6BD3A6AEACD7A97F9DB9FFA9728E31CE6B7F1FAC189D2DB7B990515404955
45DFA71D82253BBBF70A4689FF00907C0926A77A6B17E922CD811F22864D4ED75E3BB5E3D6E90241A9BA51CD4852836C72116184C8DD88C459FA2979FB6B3DEF
C3C3CC31FE622BBDE2927C76D99E586B1CCAD12D6BD2412D101B938C7EA780DDC7769AB78E8CEC4CACB13535FAEA4FEA1CB7FF003CFD91BE2FAFEEF98EC773E1
6BF35F31D9EE7BBAEDF3F77779E9D54FB4FB74FF00CEFD38DB161D84040404040404040404040404040404040404040404040404040404040404040404040404
040404040404041FFFD9}}
\par }{\fs20\lang1024\langfe1024\noproof {\shp{\*\shpinst\shpleft1440\shptop2070\shpright10800\shpbottom2070\shpfhdr1\shpbxpage\shpbxignore\shpbypage\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz2\shplockanchor\shplid2049{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn shapePath}{\sv 4}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fFilled}{\sv 0}}{\sp{\sn fArrowheadsOK}{\sv 1}}{\sp{\sn posrelh}{\sv 1}}{\sp{\sn posrelv}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxpage\dobypage\dodhgt8194\dpline\dpptx0\dppty0\dpptx9920\dppty0\dpx1190\dpy2070\dpxsize9920\dpysize0\dplinew15\dplinecor0\dplinecog0\dplinecob0}}}}{\f0\fs16  \par }}{\footerf \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }{\footer \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}} of {\field{\*\fldinst NUMPAGES}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }\pard\plain \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\fs20 {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Breg  \highlight22\uc2 Introduces \highlight\uc2  Post-operative Knee Brace and Other New Orthopedic Products\b0\par\par\uc2 719 \uc2 words\par \uc2 5 February 2013\par 08:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par New Brace Enhances Fit and Comfort for Patients Recovering from Knee Surgery \par  \f28 \par \par \uc2 \f2 CARLSBAD, Calif., Feb. 5, 2013 /PRNewswire/ -- \f28 \uc2 \f2 Breg, Inc\f28 \uc2 \f2 ., a premier provider of sports medicine products and services, announced today four \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  that will advance the orthopedic practice. The highlight of the new introduction is a next generation post-operative knee brace, the T Scope(R) Premier, for patients recovering from knee surgery and injuries. Also \f28 \b \highlight22\uc2 \f2 launched\f28 \b0 \highlight\uc2 \f2  today: the Carlsbad Cervical Collar for cervical spine immobilization; the Ultra CTS(R) Ankle Brace that converts from acute ankle support to rehabilitation; and the Achilles Wedges for foot rehabilitation.\f28 \par \par \uc2 (Photo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130205/CG53243"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130205/CG53243}}}\uc2 )\par \par \uc2 (Logo: {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20120614/MM25167LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20120614/MM25167LOGO}}}\uc2 )\par \par \uc2 "Our patients really liked the comfort of the T Scope Premier, particularly with the new incision pad," said Timothy J. Steinagle, DO, FACS, TOA Sports Medicine in Smyrna, Tennessee, and field trial site for the brace. "When patients are more comfortable, they are more compliant, which is critical for successful rehabilitation. Additionally, the range-of-motion stops on the new brace are even easier to use. Well done Breg."\par \par \uc2 "About 1.4 million knee procedures are performed in the U.S. every year and rising(1) as demographics shift to an increasingly older and active population," said \uc2 Brad Lee\uc2 , president of Breg. "We developed the T Scope Premier with input from orthopedic surgeons and patients to enhance ease of use, comfort and fit. We expect this brace to have a significant impact on the growing post-op recovery market."\par \par \uc2 The T Scope Premier builds on the telescoping design of the original T Scope which medical professionals have trusted for years. The new brace features a refined range-of-motion hinge, a simplified user interface, redesigned pads and cuffs and an optional BridgeTech Incision Pad for adjustable comfort around the incision site. The result is a high performance, comfortable knee brace designed to provide protected, controlled range-of-motion for patients recovering from knee surgery or for those who have knee injuries or instabilities.\par \par \uc2 Other new products:\par \par \uc2 \f2 \par    -- Ultra CTS(TM) Ankle Brace is the first custom treatment system that \par       transforms from acute ankle brace to low profile activity brace as the \par       patient progresses through rehabilitation. The brace's PerformaFit(TM) \par       upright stays attached for acute injury and can be detached for return to \par       activity. The Ultra CTS ankle brace features Performathane(R) technology \par       which custom forms to the injured ankle, constantly reforming with edema \par       reduction. \par  \par    -- Carlsbad Cervical Collar provides cervical spine immobilization with full \par       adjustability and comfort. The semi-rigid frame restricts flexion, \par       extension and lateral rotation. With dual height adjustments, six size \par       settings and half-size increments, patients get a personalized fit, and \par       health care professionals will always have the right size on hand. The \par       product is radiolucent for use under X-ray, CT and MRI. \par  \par    -- Achilles Wedges place the foot in planter flexion to offload the Achilles \par       tendon during rehabilitation. The wedges provide comfortable, customized \par       height adjustments with four interlocking wedges that maintain an angle \par       of plantar flexion at 5 degrees, 10 degrees, 15 degrees or 20 degrees. \par       Achilles Wedges are available for all walker boots except range-of-motion \par       (ROM) walkers and Breg's Vectra(TM) Lite Walker Boot (unless a heel clip \par       is used). \f28 \par \par \uc2 \f2 Links to multimedia assets:\f28 \par \par \uc2 \f2 T Scope Premier Application Video: \f28 {\field{\*\fldinst{HYPERLINK "http://www.breg.com/TSPA"}}{\fldrslt{\cf2 \uc2 www.breg.com/TSPA}}}\par \par \uc2 \f2 T Scope Premier Patient Video: \f28 {\field{\*\fldinst{HYPERLINK "http://www.breg.com/TS"}}{\fldrslt{\cf2 \uc2 www.breg.com/TS}}}\par \par \uc2 \f2 T Scope Premier Animation Video: \f28 {\field{\*\fldinst{HYPERLINK "http://www.breg.com/TSP"}}{\fldrslt{\cf2 \uc2 www.breg.com/TSP}}}\par \par \uc2 \f2 About \f28 \uc2 \f2 Breg, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Breg provides premium, high-value sports medicine products and services that advance orthopedic patient care. From pioneering cold therapy and innovative bracing to caring customer service and award-winning orthopedic practice solutions, Breg delivers a 360 degree customer experience unmatched in the industry. Founded in 1989, Breg is based in Carlsbad, CA, and is a company of \f28 \uc2 \f2 Water Street Healthcare Partners\f28 \uc2 \f2 , a strategic private equity firm focused exclusively on health care. Visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.breg.com"}}{\fldrslt{\cf2 \uc2 www.breg.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 1) \f28 \uc2 \f2 National Center for Health Statistics\f28 \uc2 \f2 , accessed January 9, 2013.\f28 \par \par \uc2 \f2 T Scope is a registered trademark of \f28 \uc2 \f2 Breg, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Performathane is a registered trademark, and Ultra CTS and PerformaFit are trademarks of Ultra Athlete.\f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Breg, Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020130205e92500058\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw427\pich40\picscaley100\picscalex100\picwgoal6405\pichgoal600
47
4946383961AB012800F7FF00F4F4F4656262F2F2F2D6D5D5195271ABC0CCC1D0D9326581DAD9D9E1E8EDDFE7EB3A6A85CECDCD2D292A797677504D4D6C6A6A3D
393A5D5A5BD0D0D0F0F0F04B7891ECECEC124D6DEEF2F5B2B1B16D91A5E8EEF10E496AF6F8F9A8BDC9A5A4A4658BA0A2B9C6557F96AAA8A87A7878686566BAB9
B9A6BCC89E9D9D979595DDDDDD82A1B2E3E2E2B7B5B65A8399595656BEBDBD383435265C79C9D6DEEFEFEFE6E6E62D607DADACACE4E4E47295A89DB5C3EAEAEA
CDDAE1BDCDD6F5F7F99A989989A6B68DA9B97E7C7D5F5C5CB6C8D2737171444041B3C6D1888686F8FAFB2925264C4849807E7EE9E9E9698EA2494646295E7B61
889E949293DEDEDE84818292ADBC353132302C2D706D6E828080D7E1E6D1DCE30A4768C3C2C28F8D8D2622236B6869014063A4A2A28B8989E6ECF0E4EBEE7D9D
AF517C9492909147748E8E8C8C94AEBD1D5574757273A3A1A1F0F4F696B0BE054365545152B9CAD441708ADAE3E88785855C849BB0C4CF9C9A9A413E3F3D6D88
87A5B598B1C0225977605D5E7C797AB0AEAF366883C7D5DD07446649768FD5DFE57E9EB07899AC7698AB44728C242021F8F8F8FCFBFC373334F2F5F7F6F6F646
4344F6F5F5C7C6C6332F30A8A6A7565354252122FBFBFBFCFCFCFDFDFD262323F7F7F7FAFAFA578198F9F9F92B2728FDFDFE084567333031FCFDFDF3F6F8FAFB
FC575454FBFCFD4340405B849A7B9CAEA9A7A80241633C3839CAC9C9C5C4C4393637C4D3DBCAC9CA524E4F625F604F4C4DEBF0F3BBCCD5DCDBDB5B5859777475
C4C3C4C1C0C0406F894E4B4CD2D1D23F3B3C4B4748C0BFBFC8C7C7E2E1E1C6C5C5A19FA0989697CBCACBB8B7B7D3D2D2B5B3B4C9C8C81B5373BDBBBCE0DFE020
57768583843F3C3D918F8F7E7B7C53505185A3B4EDEDEDB4B3B3E1E0E0165070E8E7E7ACABABA09E9FBFCFD8507B936A6768BCBABBD8D7D8809FB184A2B34744
459BB4C1767374726F70D8E2E7CFCECE5A5758D3DEE4C2C1C190ABBB91ACBB8C8A8BD4D3D39FB7C4ECF1F3B8CAD35F879C6D6B6BDBE4E9A0B7C56F93A68D8B8C
CBD8DF003F62231F20FFFFFF21F904010000FF002C00000000AB0128000008FF00FFFD2322A2A0414F779C94F3A040A04387490A805810ED02870B7EE8E430E0
708BC1827C042A70F151964032AA3E7AF8C7E7A3C1190E4B85B027888DC56D32D2AC82F9708ECB288F1C962159D05302059E5C2A15C1F1DF06389E0E44632363
81277205363CDCBA550A894F5CC3FE4300A62C986A9CC4AA15F8A16C386A6BE3CA9D4BB7AEDDBB78EF32E2C4176CDEBF80F1EAEB47B8B0E17E1CEED4D9BA65CF
E1C3AD5CD0FB37E3B0A050FFDE1D5E2370CD6103B7443DEE67F29F8103A30B1372E2C361A2C7E71CE23A7C0B4FEAC344FEE18976BB5FC8B9A71A40A2CBCB9F71
E370F116392E27B0F3E7D0A307E6A4CB88750899A46B772EA277E1685A1CE2FFE3EDBD5F21541B3818B661EA5F9AC3BF7D191694793407AD332E94EF17C5A1AA
C707A022900E8645F34F10E58942C60CA2F5960F5D433832DC5C932C729C3FA000831709C749B0DD872086F89724B11CF74B2322A6B8162982ECD74F050E55E0
623F27FCE38C61CE9852867A8621F24F3B841856C53FA83D26032A4914B95F0FFF84E2D863B9FD438E61BEFC339877CE74A08877AD3425578413CA55E185FEC8
D1C95D1C1AE7A18A6CB629A224111C470B8A6EBAF9C636867100851FFA1D164778DF3CB6CD027BC8F05805A1B458180749E4F3981352E6498F2C61F453A96169
FCE3C163CE2CB0801F8F81F04F076C8C06E33F5118D69F8C8585C1C5ABB072FF5181210D12C681200BD84040830DCD05265D6392890C9A1DD669ECB1810140C9
714FD089AC885A0459983E1DF840061C3C1656A31387B9400629A1747042ADFD38E30338867191800B8FA9128A0D86B9F08F02B8F4A0431C86418AAE6139D003
6E29F0B462D801FF94C1C56871F0F0CF9685ADF00FBC852D90C0C4142B704B0187D5F88F296F685100101D402821B01692D9C00076A5E9CF9ACFB6ECB2589D78
C1041342E4A1C9CB20D6B3D943A90AF98FA18B96B1D502E9DEC26D615CE071E3616718207061510A44A9614124D12761D184EC1029A016E6CC3FB23C1DEACF86
8560B5AA629D7398135AB497D7AF14964CE60B98D4A532CB38E7ADF7DEDBF5FF71181E0F957358151B484BD81E5CBD87F42D2BE4A90ABE87297234615024F190
DA86E1C1C3A58479B25512101376C13F27DC76812C578731883A90639DC6EBAFBB1072E9878962C31DE7686517DC6296BC490317E66177B17C176FFCF1752162
581C5B3CA4BC61F9048AF643A628D90F176FF85D582BD9E24880610E3FB48A61AD68E1A861AB6CE5C3D2847D7D4D6F7464CBC52D477807457B7518FE181B9CD5
C57B5CC1BA023280679C2B20802E77439E0217C8404F18E6021878C81D0E838BF315267D0F79C4F70A730152D8C63EA13B0C17D4B195FF2CAA0353320C1CB692
808315C606FF00C17AAEC6A97F54C13B67708806BCF31B5F8D2C6EC6D9442EFFD070A12164472E0964A0129788335210AD3007709B40E4B3BD3A00E1307DD88A
025C4818184EED316990A1A9B6E244C3C8E01F3BCCDC560621B67E648A618421471A47B3807FE4C03BFA70880F40D0C6C3702001220B13007D37804F2CE1426E
984B12EDC2090048C2590CEC04001C593726E605139200C0CDE2C288499E09309F9824242A1996526C9030E078880F4AC5415398E13005D88AD30C934A7C90AB
307048E16356A24AF6B93186E42B8D433665180DFCA36B84C98716FA581855FC635F84E11E07A639CDFE39A407209081FE0AC3CB2FFDB077419CC03F9AB189E3
50420548249E5C30C10B2448400F3188002DDA70036CA8051895C8272B2C10FF9761E4B3122C88CB00FE6902B120E0076058822BE2F98B1250C3188C104B17FE
79834F8A251319C8E70828109766FCB3190FD18409FED985B03422A3F99CC556A680022C3C2002D368C23DD1108048C422164B808037025A970148A104C28845
0C82610B30482119A414882D0D934787CCA08D88D32561BAD999C398E11F18A02161E250063E8C860D6FD022B9442546C284C14B02199F6174F0082EF6A31EFF
28446AD217C205DC020378C5AB141FD2812DF4E149B80C24C9C229103B5CE80F9B54CB22D7A20C3990E942D340C111B792810BB1622D0088C171BC10172C1C27
1D5C29461B08F8587F2C62096E48CB56C6702106AC05011762C65A1AF184E3FF0CCB218D10C6716A11164958E1386D70880A7671850B5D41006161400994505A
7F8C02091C8D0B02EEC1DCE67E81162320252E38D70F1DE8F10C87F191670CE3CC983CB130B81815141E5347043D26075CC19861CAF10FB51606BE0ED900D0B6
AA007E888D1086F847FD46730E54D0D01E6221852CD4A1358710E13021102C10FDB10971FE0300BA3DCE07E2B2D8B008C001CD25530968C0150B2CCB38A055CB
2CE4F602CCBAE2382DD8CA2BE214E20BC9C1B50F6180DC6E2B960F5C8809AF2D27850F885B5A1CA704BD7DB1711C20904038E2B17A50AD4334210550D4D8380F
C8C55A60F0E42BAB0965FFC05C61CE700833E8C37AFD68054C0C00C6150461FF158A2A8C0CB446C5F9FE030E8F619E02EEC08702E0A20021ECC711FE21DFED9D
E11A414044A0AB443BC26C23ACA888B361BE818FD6F543069EC8B4A63D510553F8411432A88013CCC00772483A0C3CF1A620D712AC0A3B841842762E34D6D2E1
AD60831D64DA442C9E100C2B1751125C29C17122006CB148E1420DA8815A8851322BD853B85D36CE225C210709582316973059251EF209231CE70F6BF12CB392
BA1537C829B1FF6884918D8364AEC0E93824F8C7319A6B0B483602C464B2823952415AE3A482A75C0146718F738908584202B4D06CBE3350DF199DAA03EB7511
3C1CE2C0E5292C048F419CE06E4380C9DC024F2E8AE5FBA028A07FCCE33184FF2883CECAA381B696A772120627852D5CD80BB55B2CB576C8276A71A1518C6102
00F8042454F0031A1B270B5C11C37116910CB5FC814CD9508B178EBC15611F070C93004076322180592041C9C6C1C264FFC184E35C819F618144302EB48971A8
050CC751C356D44D75771B5D1A30C8B6715CD1066F286318EBD88A618FB30907C082067BA9C1087E7121095814B72FB8503A92A1C97453C0184C88B63F803CC1
FD5CA0790269B4777CD1E02B915C378FF16EA00F83C103B9480498296B3F44E0904720D3D177DE4F1F0CC1CCC74438E68324AC430050DBE37443B1EAE40A352E
440B226F85059137CE179AFE902954D71F52100B364E7C1C21A825FAFED8B0FF43C6116BEF8BA5094860AE2D48FC10715C4819626180DE8F93480F2BFC122A7D
08DDD9DD5BA3BF80C6B18002CF1616CA7021AE50525C0100F8661C62C015B37021F1A01638C004D9A60BC02669B7E107E9F51040B04D8F410742E31023774102
311B0FF4083DD01B0B105602110A39C05DA3710611F40F75D60FF825105E353076B424C4741BAD400EBBF34DC137735B010BB1E608388073C9F71008405AC280
76616101DE661C01C01596B0840EF10CD2E66B4F406E02810304040AB3E6103E661CA3008562D10B7200660F4103D1867461810CC6A1045F601CF72051C7A107
11A57FEBE60F37F710EF4626123086620100A9701CA3A02117C573C6A10700FFB01529306CC5A6162D2007DA20100740009AB8899AE80CD17000671004641016
B21005D1200A9712067170017400070D26101EC089CEC0133CE00C9C085F93E327AAA03B0F510F2EE00C84908A84B00D15100298F10F49B0079C380F0F4106BA
B28964C589D2B8896C50073370078240005CD03A8440009EB081FE2384ACE63B34E71054702160A0846A221680701C4A806394E88ECE271044544032C5154860
1C4BD00641E4765C1108C76109E8568FFEF00B73E1175C710FC7B10490E4108C180012601CB1F0885C110FF0C615FBE787FD47264340916AA1741A1617B9405A
B2F510E7B88E7261518FB0922CC992A5E003961317A5A00506400444D0033CFF700B09D692A5E010A1500A2D490A05430440000285B00074E0092B906A61F106
EDD00336F90D5B30195B01942C29947CD59296E3032DD9952E798CA8F0080A300350890B3C308377F13FE3287C0F2100E67021371016396701A3F059EB9461FE
F0035BB10EF357920F9109EB46055A681CF5B7150B981C0E218712E99178310284378F02810D75E90FAC9007D236095CA1098E651C3136777DF8870E1188C661
043B101780B9905EC815E9701C45B015F9389A0D694971718CB2191D6AA916AD568E0EC10BB1160BCAB61539970D4B878071C15AFCC76D53B879A1E56B190000
0404015CC10887E80F97008F025159C7917D7FC102A4D5805B0103D2970B0CFF701C88E910DAE06B6788919FB99141D40B728100B1A69772819DFEA0870F0192
A6E59DB5B99F75729B62919B62719261C7153927A01339172690877BE81065671C5DB81537601CA01050D177A00F310175E80F46B0A002C10D03479D54007077
A10BC77187AEE96F8D9059C6A10B5CE198C7E99975B715A2598572E1A214C6866B010DD5A50453F010B9707D4AA006DCC09F44AA22FE191600EA6191702151F7
10393704DF46173F6A1CC9B615834961FEE810F8460B37639C8B400C5BA198FE607E27DA73E97003DA109B6B21A6162A109A600D4B2610567705F7E810CBC180
26B59E76771C803017D2701CB180906BD10925621C306098641203BB900138FF307645FAA8CE71A45C91A461E10E19EA0FAE50A7FF506B8CB0A4C61101F710AA
A23AAAA31A0042E66A0F4101D1760CC8691C482010BD909D5BF174C6210E61010011F9580D400B4C9001BF1917CB70A9B0F010DC691C71F90F96C9998048633C
9AA731BAACC7C164720101660706A47AADA10A061F3A02B606A78F75057240052D509A905AAE6F238EB8498E6BD1A0C6D19A0E516B00F05B5E5663BC909057F7
10C16AA8024103F28A373B307056C07E5C210080106B8F4509257003C8A5169880979CE510118A21C52010186A1C54F010AF503202E9AC2F0AAD712A17B93AAF
CD253CB6560472F358560001CD69AE2CEB43AB96AE6C191614909CFE007F02FF516B02F0A122FB58B6BA1536DAA628601C01EB1001608F0ED102C7019D6BF10A
58A0B38F650495806E5BF1A7C6D1625A6A1CD6B0498CA007FAE82CCB871C629191A02910A229AD6BA109A7B0B3CDA59D5CD10525D06F8FF50481D0B2742B1692
BA15942A51971A0C6887B3DC370A9110B8823BB8843BB860FA7CA435AC724A850F91ACFEE097D5701C972517C5F00110E00AF3472660B0B05C11AB543AA4FFC0
0853F8AA0EB10B41E47CD1579D61ABA7326A7466BB16E0D700853BBB85BB6D6A3105C75002B170B217B20B5256B7757BB70F91B762C1AEFE20ADB5269A4CC008
CCDBBCCEFBBCCE2BB502017E0F4B01F22A9F149BA140F60F9DE0A90D20A272FF2100AFF00325309917120E8E2A100250A8FED0A4F9EA0FCFF01036EA9D60389A
82CA87CF1A9AAE3B1745BBA2D0FBBFD0ABA65C4103C69002B5E0B4C70BBC0A2CBC0E41BC329B9C8B70A8B59691EE0A1D9158B502D105C6A1BA0EC1095CEB0F0C
F90F032064EC00183520068C77210C1716E2A69CFF10B4FE400903F80FD637A0FF0090C6B1BD1CAB917BFAB171B180C2D0262C8002C5771CEEA0C0C18BAEFFA9
AE72310CF3970A00C0AE78E3102DFC00D2FB17C090A10D30A453E70FC1B06AE83087E804C3FE9002CE010083671CBC151611EB0FC2901DD4EA0F6BEC1099F000
9F9A16ED681CF1BBBAF94BB6FB2B1717EC0F5740AE6C42012AE30F5880C474FFCBC002E1C06211B9C76107023AC502F103C7D100130B1D9850C40505A5FE50C1
0E61A3710977FEF005CB001DFDEB0F31C0980E510304A404D090094AC6630E41B55F200FFFF096FEE008D1B5C363FB0F653B179E5BAB7582B6C711098ADCB28C
FC0F8E1C1634909C4A300D58F80F13307F28201D023A069C20AF935B7DD5C5049DA0640FFA1C6D0C0ABFBA159EEC0F19900BD9C6C1ED771C95500342A6B47CDC
B1FA1BAD73C1AFC0652C644C09C9CCB2CBDCCC61E1C4A545C9FF8009B6701C46C0CA62C1020E70CE9D7B1C43D00516A204E8B4159990D0FE700ACD90A117BB16
9C1B17482BA110ED108E8B0495601CD3F0B22696C36D6CBBF5CCC3AD8BCF73FF61BA540A99300308D437B074C10AE6F4CFE61AD04C4C17902C886291D2C7210D
72010050BA0438BA15EBBB77F8F60BE9FB0F27190B2A73A852270C381D16C7661CAB2C16236C1CB66075A0FC109E9C53547A896A21B6EC99C073C100973A04A9
B91565670530E0A84CF000E01BA0C70CD4E52AD4312B1734309D8D27169090C2C681BD61D1048CE80F2F20C0FFB09AD4595D1FCD15095ACAD5150B21FD1098F0
D5B1D0996A51036B67CFFA97C297E06BDDDC151BEC6B56DBD6ACEBB1703D1777BA64F7FB109CC0AE432B108C30787A300C2229AFFE800E800DA9824D8476F10C
BC6BD002910CD737DC17FD10001008C9D900C4C9C68F555051E8B4892C16C5FF7121F7F00A8F271099000B87741CDA2D16AFE98ED1BD152B46266C1BD3BF1CCC
74510346B732D6291098D005E0E70F85F90F232D7D6D3001B189093040B3875BDC447ADCA86A17793CCD0EC10A277B05259002DDD00D79000834AB042B3CDAFD
76766A11B2C6717C8568BCD4F90B428002DD7003DE40057290B95870C50E010B276B0B557D616057CABAA99E7D0CCC7F4C17AFA0B39B20015E300237700C5460
C717529EFF4001FCC876BC8A0237D00D2890054ADE7D0AFEA80CBEE372810D1F8C926A5109701B62B1D0B37191CEFE006E6AF1B5545AD25B710C085C6325D0D9
0978DF971D160A396E71E1D63D3CDB74010B395E634A70CD619102635E63E9E8C0A1595E9B2F70052FEBDD1712787871A51B2D17B390B635760960A06573E1B8
D8B716C670212C2A17E3900E874E268E9002E32D164F6E1CE91D16DE702170385B7839C78028DCC17517530006995B5AA790E061310160F0DCCDE50A2820E38B
BE445450028AAE16F2700A9660092FD0D573B10FD16E0977AE169DC00CBA4B09DEFEEDA9000820551708F002D1FE02A7AC16001000D77EAC73810052200156F0
EDDF1E034390076E2E16C370ED4330C35C910BE66E09A7F00A7291092470ED6310169C100ED74ECB76610CBB1001F4EEEDAE80052D50D75B31005EF002F33EF1
B110006EA0A90101003B}}
\par\par \b \uc2 MARKET TALK: St Jude Sees  \highlight22\uc2 New Products \highlight\uc2  Driving 2013 Growth\b0\par\par\uc2 1,219 \uc2 words\par \uc2 1 February 2013\par 08:55\par \uc2 Dow Jones News Service\par \uc2 DJ\par \uc2 English\par \uc2 (c) 2013 Dow Jones & Company, Inc.   \par \par \uc2 8:55 EST - \uc2 St Jude Medical\uc2  (STJ) says 2013 start slowly, but growth will accelerate in 2H as \b \highlight22\uc2 new product launches\b0 \highlight\uc2  gain traction. STJ has more than 20 new medical devices slated for release, including new versions of its non-surgical heart valve replacement, Portico, in Europe. A full portfolio of Portico devices should help STJ compete with market leaders \uc2 Edwards Lifesciences\uc2  (EW) and \uc2 Medtronic\uc2  (MDT). If STJ can execute on the \b \highlight22\uc2 launches\b0 \highlight\uc2 , "one could see us really recovering our growth profile," CEO \uc2 Dan Starks\uc2  said at STJ's investor day. (joseph.walker@dowjones.com)\par \par \uc2 8:53 EST - \uc2 St Jude Medical\uc2  (STJ) CEO \uc2 Dan Starks\uc2  sees the challenges that hurt the company in 2012 continuing this year. "We are not expecting the European medical device market to rebound in 2013," he said at the firm's investor day. "We're taking it as the new normal." Pressure on the company's implanted defibrillator lead, the Durata, is also likely, potentially hurting STJ's ability to gain market share. Those factors contributed to STJ missing its original sales guidance last year by 4%, a goal that Starks said was "too aggressive." Shares flat premarket at $40.70. (joseph.walker@dowjones.com)\par \par \uc2 8:52 EST - For more than three years, U.S. natural gas prices have struggled under the weight of soaring production that outpaced fuel consumption growth. But data suggest the weight is lifting. \uc2 Global Hunter Securities\uc2  says monthly November gas-consumption data released late Thursday, which showed 7% demand growth from last year, "suggest there is a much better alignment of production to future consumption," which will prevent deep price declines. November demand rose to the highest ever for the month, while production growth rose 1.6% from a year earlier. Natural-gas futures gain 1.1% Friday to $3.370/MMBtu on the data. (jerry.dicolo@dowjones.com)\par \par \uc2 8:50 EST - \uc2 Mattel\uc2  (MAT) CEO \uc2 Bryan Stockton\uc2  gave additional color about the toy maker's 4Q sales growth, saying Monster High, Hot Wheels and strong demand for "Batman" products, as well as strong sales for the newest American Girl doll McKenna, helped offset a decline in "Cars 2" products. For preschool line \uc2 Fisher-Price\uc2 , which posted a 6% sales jump, demand was strongest for playsets, licensed \uc2 Disney\uc2  (DIS) products and recently acquired \uc2 HIT Entertainment\uc2 , which added well known brands like Thomas & Friends and Barney to MAT's portfolio. MAT down 2.3% premarket at $36.75, as results came in under Street expectations. (john.kell@dowjones.com)\par \par \uc2 8:45 EST - Ally says there's still no timeline for when it will return proceeds from international sales to the Treasury Department. That as the government-owned auto lender completes the sale of its Canadian auto-lending and deposit businesses to RBC, which paid $4.1B. Other pending deals include Ally's Mexican insurance business and several foreign operations to \uc2 General Motors (GM)\uc2 , which should close throughout the year. An Ally spokeswoman says "returning capital to \uc2 US Treasury\uc2  as soon as possible" is a priority and subject to Fed approval. A report this week from the Special Inspector General for TARP criticized Treasury for failing to have a solid plan to exit its investment in Ally. (andrew.r.johnson@dowjones.com)\par \par \uc2 8:44 EST - VIX futures extended losses after the US government's monthly jobs report for January. Front-month February contracts extended declines to 1.8%, from 1.5% earlier, trading at 14.63. If the VIX follows suit after the open, the market's so-called fear gauge might drop back below 14. The VIX finished at 14.28 Thursday, closing above 14 for a second day, after a 17-session streak below that level last month. Eight futures contracts through September traded lower, with the September contract falling to 19.40. The VIX has averaged 20.68 over the past 20 years. (kaitlyn.kiernan@dowjones.com)\par \par \uc2 8:37 EST - Manufacturing activity in China is either accelerating, or it isn't. The split between the official state reading on the sector and \uc2 HSBC\uc2 's separate reading paints an upbeat, but still-muddy picture of the health of the top copper consumer. That makes US jobs data more important than usual for copper traders. The US doesn't come through with any more clarity, though. Copper initially erases its modest losses, but doesn't show a clear direction after the Labor Department said January's jobs gain came in below expectations, with upward revisions to 2012 figures. Comex March copper is flat at $3.732, after earlier trading as low as $3.721. (matt.day@dowjones.com)\par \par \uc2 8:35 EST - US stock-index futures hold their gains following the January jobs report, with the Dow industrials remaining up around 75 points. After the open, further upside levels to watch start at yesterday's high of 13941, the peak seen Tuesday and Wednesday within the 13965-70 range and of course 14K. Support starts at yesterday's low of around 13861. (tomi.kilgore@dowjones.com)\par \par \uc2 8:34 EST - \uc2 Exxon Mobile\uc2  (XOM) CEO \uc2 Rex Tillerson\uc2  said last year that the industry is losing its shirts on US natural gas. But \uc2 Exxon\uc2  remains unflinching in its bet that America's oil and gas bounty: in Q4 it invested $4B in the U.S. upstream sector, up from $2.4B in the same period in 2011. The company also reached a record yearly capital spending, at a cool $39.8B. (angel.gonzalez@dowjones.com)\par \par \uc2 8:30 EST - Merck (MRK) CEO \uc2 Ken Frazier\uc2  says during the 4Q conference call tha the drug maker will seek out external deals for products "at all phases of development," not only the early-stage deals that he had recently indicated were MRK's sweet spot. (peter.loftus@dowjones.com)\par \par \uc2 8:29 EST - \uc2 Exxon Mobil\uc2  (XOM) has been criticized for its massive bet in natural gas in the U.S., which analysts see as shrinking its once famous returns due to persisting low prices. But 2012 has been XOM's second-best year since the record-breaking 2008, with $44.9B in earnings, versus $45.2B in 2008. Granted, the company got a big bump from downstream asset sales in Japan in the second quarter. But its diverse portfolio compensated for low natural gas prices in the U.S. XOM up 0.7% pre-market at $90.62. (angel.gonzalez@dowjones.com)\par \par \uc2 8:26 EST - VIX futures drop ahead of January jobs report. Front-month February contracts fell 1.5% to 14.67, while March futures slipped 1.3% to 15.55. That suggests investors expect the market's so-called fear gauge to trend lower after the open. VIX fell 0.3% to 14.28 yesterday. With the VIX notching 17-straight finishes below 14, the gauge averaged just 13.54 last month, down about 24% from last year's average. (kaitlyn.kiernan@dowjones.com)\par \par \uc2 \f2 \par  \par To contact the Market Talk Editors, \par Bradley Davis, 212 416-2654, bradley.davis@dowjones.com \par Kevin Kingsbury, 212 416-2354, kevin.kingsbury@dowjones.com \par \f28 \uc2 \f2 John Shipman\f28 \uc2 \f2 , 212 416-2181,john.shipman@dowjones.com \par Patrick Sullivan, 212 416-2326,Patrick.sullivan@dowjones.com \par  \f28 \par \par \uc2 \f2 [ 02-01-13 0855ET ]\f28 \par \par \uc2 4035\par \par \uc2 Document DJ00000020130201e9210007m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw427\pich40\picscaley100\picscalex100\picwgoal6405\pichgoal600
47
4946383961AB012800F7FF00F4F4F4656262F2F2F2D6D5D5195271ABC0CCC1D0D9326581DAD9D9E1E8EDDFE7EB3A6A85CECDCD2D292A797677504D4D6C6A6A3D
393A5D5A5BD0D0D0F0F0F04B7891ECECEC124D6DEEF2F5B2B1B16D91A5E8EEF10E496AF6F8F9A8BDC9A5A4A4658BA0A2B9C6557F96AAA8A87A7878686566BAB9
B9A6BCC89E9D9D979595DDDDDD82A1B2E3E2E2B7B5B65A8399595656BEBDBD383435265C79C9D6DEEFEFEFE6E6E62D607DADACACE4E4E47295A89DB5C3EAEAEA
CDDAE1BDCDD6F5F7F99A989989A6B68DA9B97E7C7D5F5C5CB6C8D2737171444041B3C6D1888686F8FAFB2925264C4849807E7EE9E9E9698EA2494646295E7B61
889E949293DEDEDE84818292ADBC353132302C2D706D6E828080D7E1E6D1DCE30A4768C3C2C28F8D8D2622236B6869014063A4A2A28B8989E6ECF0E4EBEE7D9D
AF517C9492909147748E8E8C8C94AEBD1D5574757273A3A1A1F0F4F696B0BE054365545152B9CAD441708ADAE3E88785855C849BB0C4CF9C9A9A413E3F3D6D88
87A5B598B1C0225977605D5E7C797AB0AEAF366883C7D5DD07446649768FD5DFE57E9EB07899AC7698AB44728C242021F8F8F8FCFBFC373334F2F5F7F6F6F646
4344F6F5F5C7C6C6332F30A8A6A7565354252122FBFBFBFCFCFCFDFDFD262323F7F7F7FAFAFA578198F9F9F92B2728FDFDFE084567333031FCFDFDF3F6F8FAFB
FC575454FBFCFD4340405B849A7B9CAEA9A7A80241633C3839CAC9C9C5C4C4393637C4D3DBCAC9CA524E4F625F604F4C4DEBF0F3BBCCD5DCDBDB5B5859777475
C4C3C4C1C0C0406F894E4B4CD2D1D23F3B3C4B4748C0BFBFC8C7C7E2E1E1C6C5C5A19FA0989697CBCACBB8B7B7D3D2D2B5B3B4C9C8C81B5373BDBBBCE0DFE020
57768583843F3C3D918F8F7E7B7C53505185A3B4EDEDEDB4B3B3E1E0E0165070E8E7E7ACABABA09E9FBFCFD8507B936A6768BCBABBD8D7D8809FB184A2B34744
459BB4C1767374726F70D8E2E7CFCECE5A5758D3DEE4C2C1C190ABBB91ACBB8C8A8BD4D3D39FB7C4ECF1F3B8CAD35F879C6D6B6BDBE4E9A0B7C56F93A68D8B8C
CBD8DF003F62231F20FFFFFF21F904010000FF002C00000000AB0128000008FF00FFFD2322A2A0414F779C94F3A040A04387490A805810ED02870B7EE8E430E0
708BC1827C042A70F151964032AA3E7AF8C7E7A3C1190E4B85B027888DC56D32D2AC82F9708ECB288F1C962159D05302059E5C2A15C1F1DF06389E0E44632363
81277205363CDCBA550A894F5CC3FE4300A62C986A9CC4AA15F8A16C386A6BE3CA9D4BB7AEDDBB78EF32E2C4176CDEBF80F1EAEB47B8B0E17E1CEED4D9BA65CF
E1C3AD5CD0FB37E3B0A050FFDE1D5E2370CD6103B7443DEE67F29F8103A30B1372E2C361A2C7E71CE23A7C0B4FEAC344FEE18976BB5FC8B9A71A40A2CBCB9F71
E370F116392E27B0F3E7D0A307E6A4CB88750899A46B772EA277E1685A1CE2FFE3EDBD5F21541B3818B661EA5F9AC3BF7D191694793407AD332E94EF17C5A1AA
C707A022900E8645F34F10E58942C60CA2F5960F5D433832DC5C932C729C3FA000831709C749B0DD872086F89724B11CF74B2322A6B8162982ECD74F050E55E0
623F27FCE38C61CE9852867A8621F24F3B841856C53FA83D26032A4914B95F0FFF84E2D863B9FD438E61BEFC339877CE74A08877AD3425578413CA55E185FEC8
D1C95D1C1AE7A18A6CB629A224111C470B8A6EBAF9C636867100851FFA1D164778DF3CB6CD027BC8F05805A1B458180749E4F3981352E6498F2C61F453A96169
FCE3C163CE2CB0801F8F81F04F076C8C06E33F5118D69F8C8585C1C5ABB072FF5181210D12C681200BD84040830DCD05265D6392890C9A1DD669ECB1810140C9
714FD089AC885A0459983E1DF840061C3C1656A31387B9400629A1747042ADFD38E30338867191800B8FA9128A0D86B9F08F02B8F4A0431C86418AAE6139D003
6E29F0B462D801FF94C1C56871F0F0CF9685ADF00FBC852D90C0C4142B704B0187D5F88F296F685100101D402821B01692D9C00076A5E9CF9ACFB6ECB2589D78
C1041342E4A1C9CB20D6B3D943A90AF98FA18B96B1D502E9DEC26D615CE071E3616718207061510A44A9614124D12761D184EC1029A016E6CC3FB23C1DEACF86
8560B5AA629D7398135AB497D7AF14964CE60B98D4A532CB38E7ADF7DEDBF5FF71181E0F957358151B484BD81E5CBD87F42D2BE4A90ABE87297234615024F190
DA86E1C1C3A58479B25512101376C13F27DC76812C578731883A90639DC6EBAFBB1072E9878962C31DE7686517DC6296BC490317E66177B17C176FFCF1752162
581C5B3CA4BC61F9048AF643A628D90F176FF85D582BD9E24880610E3FB48A61AD68E1A861AB6CE5C3D2847D7D4D6F7464CBC52D477807457B7518FE181B9CD5
C57B5CC1BA023280679C2B20802E77439E0217C8404F18E6021878C81D0E838BF315267D0F79C4F70A730152D8C63EA13B0C17D4B195FF2CAA0353320C1CB692
808315C606FF00C17AAEC6A97F54C13B67708806BCF31B5F8D2C6EC6D9442EFFD070A12164472E0964A0129788335210AD3007709B40E4B3BD3A00E1307DD88A
025C4818184EED316990A1A9B6E244C3C8E01F3BCCDC560621B67E648A618421471A47B3807FE4C03BFA70880F40D0C6C3702001220B13007D37804F2CE1426E
984B12EDC2090048C2590CEC04001C593726E605139200C0CDE2C288499E09309F9824242A1996526C9030E078880F4AC5415398E13005D88AD30C934A7C90AB
307048E16356A24AF6B93186E42B8D433665180DFCA36B84C98716FA581855FC635F84E11E07A639CDFE39A407209081FE0AC3CB2FFDB077419CC03F9AB189E3
50420548249E5C30C10B2448400F3188002DDA70036CA8051895C8272B2C10FF9761E4B3122C88CB00FE6902B120E0076058822BE2F98B1250C3188C104B17FE
79834F8A251319C8E70828109766FCB3190FD18409FED985B03422A3F99CC556A680022C3C2002D368C23DD1108048C422164B808037025A970148A104C28845
0C82610B30482119A414882D0D934787CCA08D88D32561BAD999C398E11F18A02161E250063E8C860D6FD022B9442546C284C14B02199F6174F0082EF6A31EFF
28446AD217C205DC020378C5AB141FD2812DF4E149B80C24C9C229103B5CE80F9B54CB22D7A20C3990E942D340C111B792810BB1622D0088C171BC10172C1C27
1D5C29461B08F8587F2C62096E48CB56C6702106AC05011762C65A1AF184E3FF0CCB218D10C6716A11164958E1386D70880A7671850B5D41006161400994505A
7F8C02091C8D0B02EEC1DCE67E81162320252E38D70F1DE8F10C87F191670CE3CC983CB130B81815141E5347043D26075CC19861CAF10FB51606BE0ED900D0B6
AA007E888D1086F847FD46730E54D0D01E6221852CD4A1358710E13021102C10FDB10971FE0300BA3DCE07E2B2D8B008C001CD25530968C0150B2CCB38A055CB
2CE4F602CCBAE2382DD8CA2BE214E20BC9C1B50F6180DC6E2B960F5C8809AF2D27850F885B5A1CA704BD7DB1711C20904038E2B17A50AD4334210550D4D8380F
C8C55A60F0E42BAB0965FFC05C61CE700833E8C37AFD68054C0C00C6150461FF158A2A8C0CB446C5F9FE030E8F619E02EEC08702E0A20021ECC711FE21DFED9D
E11A414044A0AB443BC26C23ACA888B361BE818FD6F543069EC8B4A63D510553F8411432A88013CCC00772483A0C3CF1A620D712AC0A3B841842762E34D6D2E1
AD60831D64DA442C9E100C2B1751125C29C17122006CB148E1420DA8815A8851322BD853B85D36CE225C210709582316973059251EF209231CE70F6BF12CB392
BA1537C829B1FF6884918D8364AEC0E93824F8C7319A6B0B483602C464B2823952415AE3A482A75C0146718F738908584202B4D06CBE3350DF199DAA03EB7511
3C1CE2C0E5292C048F419CE06E4380C9DC024F2E8AE5FBA028A07FCCE33184FF2883CECAA381B696A772120627852D5CD80BB55B2CB576C8276A71A1518C6102
00F8042454F0031A1B270B5C11C37116910CB5FC814CD9508B178EBC15611F070C93004076322180592041C9C6C1C264FFC184E35C819F618144302EB48971A8
050CC751C356D44D75771B5D1A30C8B6715CD1066F286318EBD88A618FB30907C082067BA9C1087E7121095814B72FB8503A92A1C97453C0184C88B63F803CC1
FD5CA0790269B4777CD1E02B915C378FF16EA00F83C103B9480498296B3F44E0904720D3D177DE4F1F0CC1CCC74438E68324AC430050DBE37443B1EAE40A352E
440B226F85059137CE179AFE902954D71F52100B364E7C1C21A825FAFED8B0FF43C6116BEF8BA5094860AE2D48FC10715C4819626180DE8F93480F2BFC122A7D
08DDD9DD5BA3BF80C6B18002CF1616CA7021AE50525C0100F8661C62C015B37021F1A01638C004D9A60BC02669B7E107E9F51040B04D8F410742E31023774102
311B0FF4083DD01B0B105602110A39C05DA3710611F40F75D60FF825105E353076B424C4741BAD400EBBF34DC137735B010BB1E608388073C9F71008405AC280
76616101DE661C01C01596B0840EF10CD2E66B4F406E02810304040AB3E6103E661CA3008562D10B7200660F4103D1867461810CC6A1045F601CF72051C7A107
11A57FEBE60F37F710EF4626123086620100A9701CA3A02117C573C6A10700FFB01529306CC5A6162D2007DA20100740009AB8899AE80CD17000671004641016
B21005D1200A9712067170017400070D26101EC089CEC0133CE00C9C085F93E327AAA03B0F510F2EE00C84908A84B00D15100298F10F49B0079C380F0F4106BA
B28964C589D2B8896C50073370078240005CD03A8440009EB081FE2384ACE63B34E71054702160A0846A221680701C4A806394E88ECE271044544032C5154860
1C4BD00641E4765C1108C76109E8568FFEF00B73E1175C710FC7B10490E4108C180012601CB1F0885C110FF0C615FBE787FD47264340916AA1741A1617B9405A
B2F510E7B88E7261518FB0922CC992A5E003961317A5A00506400444D0033CFF700B09D692A5E010A1500A2D490A05430440000285B00074E0092B906A61F106
EDD00336F90D5B30195B01942C29947CD59296E3032DD9952E798CA8F0080A300350890B3C308377F13FE3287C0F2100E67021371016396701A3F059EB9461FE
F0035BB10EF357920F9109EB46055A681CF5B7150B981C0E218712E99178310284378F02810D75E90FAC9007D236095CA1098E651C3136777DF8870E1188C661
043B101780B9905EC815E9701C45B015F9389A0D694971718CB2191D6AA916AD568E0EC10BB1160BCAB61539970D4B878071C15AFCC76D53B879A1E56B190000
0404015CC10887E80F97008F025159C7917D7FC102A4D5805B0103D2970B0CFF701C88E910DAE06B6788919FB99141D40B728100B1A69772819DFEA0870F0192
A6E59DB5B99F75729B62919B62719261C7153927A01339172690877BE81065671C5DB81537601CA01050D177A00F310175E80F46B0A002C10D03479D54007077
A10BC77187AEE96F8D9059C6A10B5CE198C7E99975B715A2598572E1A214C6866B010DD5A50453F010B9707D4AA006DCC09F44AA22FE191600EA6191702151F7
10393704DF46173F6A1CC9B615834961FEE810F8460B37639C8B400C5BA198FE607E27DA73E97003DA109B6B21A6162A109A600D4B2610567705F7E810CBC180
26B59E76771C803017D2701CB180906BD10925621C306098641203BB900138FF307645FAA8CE71A45C91A461E10E19EA0FAE50A7FF506B8CB0A4C61101F710AA
A23AAAA31A0042E66A0F4101D1760CC8691C482010BD909D5BF174C6210E61010011F9580D400B4C9001BF1917CB70A9B0F010DC691C71F90F96C9998048633C
9AA731BAACC7C164720101660706A47AADA10A061F3A02B606A78F75057240052D509A905AAE6F238EB8498E6BD1A0C6D19A0E516B00F05B5E5663BC909057F7
10C16AA8024103F28A373B307056C07E5C210080106B8F4509257003C8A5169880979CE510118A21C52010186A1C54F010AF503202E9AC2F0AAD712A17B93AAF
CD253CB6560472F358560001CD69AE2CEB43AB96AE6C191614909CFE007F02FF516B02F0A122FB58B6BA1536DAA628601C01EB1001608F0ED102C7019D6BF10A
58A0B38F650495806E5BF1A7C6D1625A6A1CD6B0498CA007FAE82CCB871C629191A02910A229AD6BA109A7B0B3CDA59D5CD10525D06F8FF50481D0B2742B1692
BA15942A51971A0C6887B3DC370A9110B8823BB8843BB860FA7CA435AC724A850F91ACFEE097D5701C972517C5F00110E00AF3472660B0B05C11AB543AA4FFC0
0853F8AA0EB10B41E47CD1579D61ABA7326A7466BB16E0D700853BBB85BB6D6A3105C75002B170B217B20B5256B7757BB70F91B762C1AEFE20ADB5269A4CC008
CCDBBCCEFBBCCE2BB502017E0F4B01F22A9F149BA140F60F9DE0A90D20A272FF2100AFF00325309917120E8E2A100250A8FED0A4F9EA0FCFF01036EA9D60389A
82CA87CF1A9AAE3B1745BBA2D0FBBFD0ABA65C4103C69002B5E0B4C70BBC0A2CBC0E41BC329B9C8B70A8B59691EE0A1D9158B502D105C6A1BA0EC1095CEB0F0C
F90F032064EC00183520068C77210C1716E2A69CFF10B4FE400903F80FD637A0FF0090C6B1BD1CAB917BFAB171B180C2D0262C8002C5771CEEA0C0C18BAEFFA9
AE72310CF3970A00C0AE78E3102DFC00D2FB17C090A10D30A453E70FC1B06AE83087E804C3FE9002CE010083671CBC151611EB0FC2901DD4EA0F6BEC1099F000
9F9A16ED681CF1BBBAF94BB6FB2B1717EC0F5740AE6C42012AE30F5880C474FFCBC002E1C06211B9C76107023AC502F103C7D100130B1D9850C40505A5FE50C1
0E61A3710977FEF005CB001DFDEB0F31C0980E510304A404D090094AC6630E41B55F200FFFF096FEE008D1B5C363FB0F653B179E5BAB7582B6C711098ADCB28C
FC0F8E1C1634909C4A300D58F80F13307F28201D023A069C20AF935B7DD5C5049DA0640FFA1C6D0C0ABFBA159EEC0F19900BD9C6C1ED771C95500342A6B47CDC
B1FA1BAD73C1AFC0652C644C09C9CCB2CBDCCC61E1C4A545C9FF8009B6701C46C0CA62C1020E70CE9D7B1C43D00516A204E8B4159990D0FE700ACD90A117BB16
9C1B17482BA110ED108E8B0495601CD3F0B22696C36D6CBBF5CCC3AD8BCF73FF61BA540A99300308D437B074C10AE6F4CFE61AD04C4C17902C886291D2C7210D
72010050BA0438BA15EBBB77F8F60BE9FB0F27190B2A73A852270C381D16C7661CAB2C16236C1CB66075A0FC109E9C53547A896A21B6EC99C073C100973A04A9
B91565670530E0A84CF000E01BA0C70CD4E52AD4312B1734309D8D27169090C2C681BD61D1048CE80F2F20C0FFB09AD4595D1FCD15095ACAD5150B21FD1098F0
D5B1D0996A51036B67CFFA97C297E06BDDDC151BEC6B56DBD6ACEBB1703D1777BA64F7FB109CC0AE432B108C30787A300C2229AFFE800E800DA9824D8476F10C
BC6BD002910CD737DC17FD10001008C9D900C4C9C68F555051E8B4892C16C5FF7121F7F00A8F271099000B87741CDA2D16AFE98ED1BD152B46266C1BD3BF1CCC
74510346B732D6291098D005E0E70F85F90F232D7D6D3001B189093040B3875BDC447ADCA86A17793CCD0EC10A277B05259002DDD00D79000834AB042B3CDAFD
76766A11B2C6717C8568BCD4F90B428002DD7003DE40057290B95870C50E010B276B0B557D616057CABAA99E7D0CCC7F4C17AFA0B39B20015E300237700C5460
C717529EFF4001FCC876BC8A0237D00D2890054ADE7D0AFEA80CBEE372810D1F8C926A5109701B62B1D0B37191CEFE006E6AF1B5545AD25B710C085C6325D0D9
0978DF971D160A396E71E1D63D3CDB74010B395E634A70CD619102635E63E9E8C0A1595E9B2F70052FEBDD1712787871A51B2D17B390B635760960A06573E1B8
D8B716C670212C2A17E3900E874E268E9002E32D164F6E1CE91D16DE702170385B7839C78028DCC17517530006995B5AA790E061310160F0DCCDE50A2820E38B
BE445450028AAE16F2700A9660092FD0D573B10FD16E0977AE169DC00CBA4B09DEFEEDA9000820551708F002D1FE02A7AC16001000D77EAC73810052200156F0
EDDF1E034390076E2E16C370ED4330C35C910BE66E09A7F00A7291092470ED6310169C100ED74ECB76610CBB1001F4EEEDAE80052D50D75B31005EF002F33EF1
B110006EA0A90101003B}}
\par\par \b \uc2 MARKET TALK: St Jude Sees  \highlight22\uc2 New Products \highlight\uc2  Driving 2013 Growth\b0\par\par\uc2 123 \uc2 words\par \uc2 1 February 2013\par 08:55\par \uc2 Dow Jones News Service\par \uc2 DJ\par \uc2 English\par \uc2 (c) 2013 Dow Jones & Company, Inc.   \par \par \uc2 8:55 EST - \uc2 St Jude Medical\uc2  (STJ) says 2013 start slowly, but growth will accelerate in 2H as \b \highlight22\uc2 new product launches\b0 \highlight\uc2  gain traction. STJ has more than 20 new medical devices slated for release, including new versions of its non-surgical heart valve replacement, Portico, in Europe. A full portfolio of Portico devices should help STJ compete with market leaders \uc2 Edwards Lifesciences\uc2  (EW) and \uc2 Medtronic\uc2  (MDT). If STJ can execute on the \b \highlight22\uc2 launches\b0 \highlight\uc2 , "one could see us really recovering our growth profile," CEO \uc2 Dan Starks\uc2  said at STJ's investor day. (joseph.walker@dowjones.com)\par \par \uc2 Call us at (212) 416-2181 or john.shipman@dowjones.com [ 02-01-13 0855ET ]\par \par \uc2 80000\par \par \uc2 Document DJ00000020130201e9210007l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F700002A4A9CD1D8EA95A4CE4964AAF0F2F85871B18598C6768BBF3957A3E1E5F1677EB8B3BEDCA4B1D5C2CBE3F2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5C5CDE4E0E4F0F1F3F8F5F7FBE1E6F1D5DBEBF7F8FBD9DEEDEEF0F7DFE3F0D4DAEBE3E7F2D7DDECBFC8E1BBC5DFFDFEFEEBEEF6FBFCFDCED5
E8DBE0EEFAFAFC9DABD1AEBAD99EACD2E4E8F2F6F7FBF3F5FAE7EAF4E7EBF4D2D9EAE8EBF4C2CBE2E6E9F3AFBAD9C9D1E6AFBADAA8B5D74F69AE90A0CBCCD4E8
DADFED9FADD3E6EAF3DADFEEAFBBDAD5DBECD9DFEEA1AFD3DDE2EFEEF1F7D2D8E9EFF1F8E9ECF5F5F6FA798DC0798CC0DEE3F0BAC4DFE4E8F3DCE0EEA6B3D5D0
D6E9CBD2E791A1CC7388BFEDEFF7ABB7D73A56A3BEC7E1566EB1C2CAE3F3F5F9B7C1DED3DAEB6C81BBCCD3E7ECEEF6C1CAE2EDEFF6D3DAEA9DABD2D6DCECEFF1
F7C9D1E5C7CFE5C0C9E1FDFDFE94A3CDF5F7FAD0D7E9B7C2DE899AC8E2E6F2D1D7E9FEFFFFA5B2D5D1D7EAB0BBDAFCFDFEA7B4D6E9EDF5FAFAFDD8DEECAEBADA
ADB9D9DCE1EFCBD3E793A2CC8597C6CFD6E9FEFEFEE5E9F37D8FC298A7D0B9C3DFB6C0DDD9DFEDF9FAFCE2E7F2FEFEFFDDE2F06E83BC4E68AD8395C599A8D099
A8CF1B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A1428491280041019549434
B1A3C78F204336DC38E06102001B45AA5CC9B2E5C18D920C381C00D3A5CD9B3821564429690143033B2BE61C4AB468C502052C624C18A0E2019E071148125010
C080A50207001048C022C105310502855931C04001921010207892ACA40393D0BAED3989A659AE924A0AE409536F5399939A1620D8558140B06ED53A3CDAA0A2
DE8304A4AA4D595000800200D60E4409C067D6AD93BA823E1C761250AA901128282D102DEAD079AB8ECE2AE92EECC756091EA81DB874D3BC4B0B0B5C6D3BAE01
AC0B8F9A768A70355DCA034F1A2000C0F0E60152016BC53B1B2CE0D3089F12FF006ADB3541060601CCAECB1B2FEEC793769BFD2B50B045F4C22711F7A89CFD54
831A9506DD7008B446D75E0A10905401046C075B77A58D55D16BBD5115D963E60D749C6C05D9355057B8B9E5976F530520D501F9ED8758459E31D45F5BED09D4
9662930CB8E246052228D06E0820009A685F45F89F413491855A86B771489087EE5D17180008D8465F85A125459375FB6978A08B920C465A5A9AF967DB80AA05
895A750331C0D966737D372441681587DD5A729105DF24EA159494884E3ED9597D24BE361696736D995C97040D2A5645805124D4A20D740880596846E7607C73
45BA1C859324808097038165188C30A147509EE7CDF55A6EF5A144D5944D51FFB840A50192452397A0D2566245390E34E0446A8C20D01C1A4CE2011245253B54
7FD1F124558C8E72F411059AA6D0C22487F4A1ECB636311B2A4C9CD6F8A847265030C90A124C32C5059370400106DCC61B92B703ED169B41BF3E94C20B45B831
09185D48004915246801850376C8AB7047F472251572BE8E1BD10A11B8A0C2246BB0D0E92417C06B43064414B7F0C80A355C5F8B05E5EBD00E1784F145428A10
E0800B24D75C32A211A9ACD0106F4C42080B1F20B2D00651741081CD481364F2A1D23EF444069380E083430F38F040D258C7DB861891185210014F6D7480591A
5470421E59A73DD42293340275410D58656A00AB51F580CC6AE7ED92145724FF314919570F142B800310C086057A27BE9205224CF2400E4E1054C09D8A577E93
17637C2D89A909BD55D0B3380E4716467B6EA4A9AF705104579DCC597ED31233C00DED4BA9CBF8265A0221903AD86615D0AB407BA2E7B9EA7149B2D401B9BAAE
D2237F4C62441604352632BEB5777ABBB4A5571469E99C2B5DBBE7AC0FAFFC4A85DC31090C67106628ED6C5D1FDA014B25B0F924BE97FCFDEAC68F9F93155418
8414D3CA011DAF724796ED15B04364410F5A20A63F96FC40041598004106571006146E1212085C033778101EEC61127A2083EC06A0A90024852A1DA8000438C8
C2826001102388C14112602FA7DCC5021C58610B7728101438C20C359020437F98D0010E2482873C14C4B542F0818540C0015044221241A0043900210411E8C1
41503089137840088390220F4BB085496C000E1AA043095E80864EADA50E7138820EC528451AF061123A500104FC10810098400651C3C006E828C60FDC601224
F0800402C185493062026920A424078283209CAF0902C1C32437C949960404003B}}
\par\par \b \uc2 IGI Laboratories \highlight22\uc2 Introduces \highlight\uc2  9th ANDA Submission\b0\par\par\uc2 138 \uc2 words\par \uc2 31 January 2013\par \uc2 Manufacturing Close-Up\par \uc2 MFGCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 IGI Laboratories, Inc\uc2 ., a generic topical pharmaceutical company, announced it has submitted an additional abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  application (ANDA) to the US FDA, which brings the company's total number of submissions to nine.\par \par \uc2 Jason Grenfell-Gardner\uc2 , President and CEO of the Company, noted, "Our first ANDA was submitted to the US FDA in September of 2010, so in less than twenty-eight months we have successfully submitted nine ANDAs. The US FDA reports an average review time of thirty-two months, which makes us believe, we could see our first ANDA approval in 2013. We expect to file at least six ANDAs in 2013, as we are dedicated to expanding our development pipeline, and increasing our \uc2 IGI\uc2  product portfolio."\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document MFGCLU0020130131e91v00048\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw200\pich25\picscaley100\picscalex100\picwgoal3000\pichgoal375
47
4946383961C8001900B3FF00C0C0C01010102121213131314242425252526363637373737B7B7B8C8C8C9C9C9CADADADBDBDBDDEDEDE00000000000021F90401
000000002C00000000C80019004004FF10C849ABBD38EBCDBBFF60288E21E13094E34CA62A488893488753488A6354260AD4AA804292B009548E21807154DD00
8A00326061380893D82D869058B180A66A683801A440C760920E2C242DD52E3AB5C4A43B400FD088AFAD4F0B0E547C0E2F62491E712E6F1352032A0713822F12
474A159013900252605F132A382A0368456A9C0D155648A4AA0D5241523986266E7A667B005C129001BEB083045208A703A915BC5E2A3E5202476B122AAA0065
792EB68D24DBDCDDDEDFE0E1DF0CE43EE213E6E71AE5E4DB0760EA170DE95EF11CBA7032CABB57004509051C34B892A30B8F13A096AD480840D42224505AC143
D74FC2C015CA12C632940F852E2EACFF5A39E80229C8105A2A26C2181991408F1822CDD828B200D240301B2BD9DBC9B3A7CF9F40830A1D4AD4822E20F4BAE1FB
09AA011D4C1FDE0585990757529F4B4D74513321E08C41854485597110859409456E5889D6704591AA6AD6AE8B6930633FB114F69868C44B0AB5800BF652909B
814B112C7B384A386BC2928A196504912D6166E50BC23F1C481A2BC35F900B89270BFA53B12DBFCD1804A964685A996A0B0E7355E6851703A474AF29D8658699
42191BD26A879A5C74022DA8C5932B5FCEBCB9F3E7D0A34B9F4EBDBAF38702B4815BEA332412D4205418F409939A55A2F86AE8E443CF7C87A5ED302425E77EC9
D525A56B7C325F3F7E86A4F3B4E79FFF17F7C12450478355509F7CF7619055229074510415823C7104216520B7470D05CC23050AAC10B0C0847C7C0840405B05
80C2024F0C56510347A060171690CC500D82B620C0408D99A905560D3B3480C01083ACD862169AF9755E84FC6001563562E560008F372A52593EC56886E40D01
79E6D5406CB120135B5650C190280119508E28722CB0207E039083C01192CC0800240440A5D76C2CF1C6401908A89780396DBEC94B8C3D14112739B7FDD35040
371C71274194A5234A0C55C500860D0120A619716292A3187E0B9516DB78AB1C80C62AA54DCA809D5E2400CD791F8DC44A060AB4808EAA5AEAC6D2A4316A7A41
00017419430D362E212B57EFF1E9409E23972C56D96FC355959719D6F4C2D2992B5CE4C3016E26400DA6AC82D140195868C107246B8C67C50B7BFAC04B192DDE
A080361F8ABB92B5FC8CD7020A4718A480C08F495B89BBA372C0CE9B03A35A4F8216E44088040B20808076E9F8D74002C54CE094C5DA0DC68E821C2B6163C543
42BC84C70C9887B236AF1643CDC717CBD3B2C814349CB139F3B86C3172CB21F0A67544176DF4D14827AD34751100003B}}
\par\par \b \uc2 2nd UPDATE: \uc2 Biogen\uc2  Profits Slide as Costs Rise Ahead of Drug  \highlight22\uc2 Launch \highlight\b0\par\par\uc2 1,031 \uc2 words\par \uc2 28 January 2013\par 12:48\par \uc2 Dow Jones Global News Select\par \uc2 DJON\par \uc2 English\par \uc2 (c) 2013 Dow Jones & Company, Inc.   \par \par \uc2 --\uc2 Biogen\uc2  sales and marketing costs rise 32% ahead of \b \highlight22\uc2 new drug launch\b0 \highlight\par \par \uc2 --Defends safety of BG-12, an experimental MS drug pending FDA approval\par \par \uc2 --Sales of \uc2 Biogen\uc2 's biggest drug, Avonex, rise 7%\par \par \uc2 (Adds company and analyst comments, updates stock price.)\par \par \uc2 \f2 \par  \par    By Joseph Walker \par  \f28 \par \par \uc2 \f2 Biogen Idec Inc\f28 \uc2 \f2 .'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased its expenses, masking revenue growth of its existing MS treatment.\f28 \par \par \uc2 \f2 The company is awaiting a decision by the \f28 \uc2 \f2 U.S. Food and Drug Administration\f28 \uc2 \f2  on its MS therapy BG-12, which the firm said Monday it will market under the brand name Tecfidera. \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  shares have soared 27% in the past year on hopes that the oral-pill therapy could eventually generate $3 billion annually.\f28 \par \par \uc2 \f2 An FDA ruling is expected by late March, but promotional planning and increased salesforce costs for an anticipated launch of Tecfidera drove up \f28 \uc2 \f2 Biogen\f28 \uc2 \f2 's selling, general and administrative costs by 32% in the fourth and 21% through 2012.\f28 \par \par \uc2 \f2 The company defended the increased spending, saying the Tecfidera launch presents a unique market opportunity. The spending will continue to increase in 2013, \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  said.\f28 \par \par \uc2 \f2 For 2013, \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters had forecast $7.27 a share on a 9% rise in revenue to $5.98 billion.\f28 \par \par \uc2 \f2 Analysts interpreted the higher-than-expected revenue projection as a positive signal for initial Tecfidera sales, helping to lift \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  shares recently 3% to $150.57.\f28 \par \par \uc2 \f2 "There were some fears that this company, which historically has guided quite conservatively, would go out of its way to do that again and, in particular, talk down expectations for [Tecfidera]," said Eric Schmidt, a Cowen and Co. analyst. "This was a pleasant surprise."\f28 \par \par \uc2 \f2 Biogen\f28 \uc2 \f2  didn't specify its revenue expectation for the new drug, but ISI Group analyst Mark Schoenebaum said the company's total revenue forecast suggests an outlook between $350 million and $450 million, which matches well with Wall Street's high-end expectation of $400 million.\f28 \par \par \uc2 \f2 The company said it expects European approval for the drug by mid-2013, but, because of reimbursement schedules on the continent, much of the revenue from sales wouldn't come in until 2014.\f28 \par \par \uc2 \f2 Chief Financial Officer \f28 \uc2 \f2 Paul Clancy\f28 \uc2 \f2  also cautioned that patients switching from injectable medication to Tecfidera, which is a pill, may not consistently take the prescribed two doses per day, potentially hurting volume.\f28 \par \par \uc2 \f2 "There's a good chance that compliance, the number of pills a patient takes in a given week may be lower" than the label recommends, Mr. Clancy said. "It's a little bit of an unknowable because MS patients haven't for a long time been afforded the opportunity for oral drugs."\f28 \par \par \uc2 \f2 The company was forced to respond Monday to concerns about the drug raised by competitor \f28 \uc2 \f2 Teva Pharmaceutical Industries Ltd\f28 \uc2 \f2 . (TEVA), which earlier this month formally asked that the FDA not approve Tecfidera until an advisory committee is convened to consider the potential for health risks, including kidney problems found in animal testing.\f28 \par \par \uc2 \f2 "You may have noticed there has been some noise from competitors which is not surprising," Biogen Chief Executive \f28 \uc2 \f2 George Scangos\f28 \uc2 \f2  said. "I take the noise to be more a reflection of competitive worries about [Tecfidera] more than anything else."\f28 \par \par \uc2 \f2 Mr. Scangos noted that clinical trials hadn't turned up any kidney problems in humans.\f28 \par \par \uc2 \f2 The FDA's decision was delayed three months from December. \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  has downplayed the significance of the delay, saying that it doesn't necessarily signal problems with Tecfidera.\f28 \par \par \uc2 \f2 "Teva succeeded in making some folks a little jittery, but from where I sit, there's nothing to be fearful about," Cowen's Mr. Schmidt said. "I think this approval is a slam dunk."\f28 \par \par \uc2 \f2 As a pill, Tecfidera is thought to be more effective and convenient than \f28 \uc2 \f2 Biogen\f28 \uc2 \f2 's current injectable drugs. Competitors, however, have brought their own pill-based drugs to market earlier, including \f28 \uc2 \f2 Sanofi S.A\f28 \uc2 \f2 . (SAN.FR).\f28 \par \par \uc2 \f2 Biogen\f28 \uc2 \f2 's fourth-quarter sales rose 7% to $1.4 billion, driven largely by increased revenues from MS-therapy Avonex, the firm's biggest-selling drug. Last week, \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  said it completed a successful late-stage trial for a longer-acting version of Avonex, which analysts said could help the company gain market share from competitors if it is approved by the \f28 \uc2 \f2 Food and Drug Administration\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 The company reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding certain items, per-share earnings fell to $1.40 from $1.51 and missed Wall Street estimates of $1.46 a share, according to analysts polled by Thomson Reuters.\f28 \par \par \uc2 \f2 Research and development costs rose 1.8% in the latest period as the company looks to develop new drugs for degenerative neurological diseases, including MS.\f28 \par \par \uc2 \f2 -Melodie Warner contributed to this article.\f28 \par \par \uc2 \f2 Write to Joseph Walker at joseph.walker@dowjones.com\f28 \par \par \uc2 \f2 Corrections & Amplifications\f28 \par \par \uc2 \f2 This article was corrected Jan. 29 at 11:26 a.m. EST because the original version misstated the action taken by \f28 \uc2 \f2 Teva Pharmaceutical Industries Ltd\f28 \uc2 \f2 . in the twelfth paragraph. Teva asked that the FDA not approve Tecfidera until an advisory committee is convened to consider the potential for health risks, including kidney problems found in animal testing, not that the FDA deny approval for Tecfidera, an experimental drug from \f28 \uc2 \f2 Biogen Idec Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Subscribe to WSJ: \f28 {\field{\*\fldinst{HYPERLINK "http://online.wsj.com?mod=djnwires"}}{\fldrslt{\cf2 \uc2 http://online.wsj.com?mod=djnwires}}}\uc2 \f2  [ 01-28-13 1248ET ]\f28 \par \par \uc2 \f2 "2nd UPDATE: \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  Profits Slide as Costs Rise Ahead of Drug Launch," published at 12:33 p.m. EST Jan. 28, misstated the action taken by \f28 \uc2 \f2 Teva Pharmaceutical Industries Ltd\f28 \uc2 \f2 . in the twelfth paragraph. Teva asked that the FDA not approve Tecfidera until an advisory committee is convened to consider the potential for health risks, including kidney problems found in animal testing, not that the FDA deny approval for Tecfidera, an experimental drug from \f28 \uc2 \f2 Biogen Idec Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Subscribe to WSJ: \f28 {\field{\*\fldinst{HYPERLINK "http://online.wsj.com?mod=djnwires"}}{\fldrslt{\cf2 \uc2 http://online.wsj.com?mod=djnwires}}}\uc2 \f2  [ 01-29-13 1140ET ]\f28 \par \par \uc2 Document DJON000020130129e91s0005r\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw200\pich25\picscaley100\picscalex100\picwgoal3000\pichgoal375
47
4946383961C8001900B3FF00C0C0C01010102121213131314242425252526363637373737B7B7B8C8C8C9C9C9CADADADBDBDBDDEDEDE00000000000021F90401
000000002C00000000C80019004004FF10C849ABBD38EBCDBBFF60288E21E13094E34CA62A488893488753488A6354260AD4AA804292B009548E21807154DD00
8A00326061380893D82D869058B180A66A683801A440C760920E2C242DD52E3AB5C4A43B400FD088AFAD4F0B0E547C0E2F62491E712E6F1352032A0713822F12
474A159013900252605F132A382A0368456A9C0D155648A4AA0D5241523986266E7A667B005C129001BEB083045208A703A915BC5E2A3E5202476B122AAA0065
792EB68D24DBDCDDDEDFE0E1DF0CE43EE213E6E71AE5E4DB0760EA170DE95EF11CBA7032CABB57004509051C34B892A30B8F13A096AD480840D42224505AC143
D74FC2C015CA12C632940F852E2EACFF5A39E80229C8105A2A26C2181991408F1822CDD828B200D240301B2BD9DBC9B3A7CF9F40830A1D4AD4822E20F4BAE1FB
09AA011D4C1FDE0585990757529F4B4D74513321E08C41854485597110859409456E5889D6704591AA6AD6AE8B6930633FB114F69868C44B0AB5800BF652909B
814B112C7B384A386BC2928A196504912D6166E50BC23F1C481A2BC35F900B89270BFA53B12DBFCD1804A964685A996A0B0E7355E6851703A474AF29D8658699
42191BD26A879A5C74022DA8C5932B5FCEBCB9F3E7D0A34B9F4EBDBAF38702B4815BEA332412D4205418F409939A55A2F86AE8E443CF7C87A5ED302425E77EC9
D525A56B7C325F3F7E86A4F3B4E79FFF17F7C12450478355509F7CF7619055229074510415823C7104216520B7470D05CC23050AAC10B0C0847C7C0840405B05
80C2024F0C56510347A060171690CC500D82B620C0408D99A905560D3B3480C01083ACD862169AF9755E84FC6001563562E560008F372A52593EC56886E40D01
79E6D5406CB120135B5650C190280119508E28722CB0207E039083C01192CC0800240440A5D76C2CF1C6401908A89780396DBEC94B8C3D14112739B7FDD35040
371C71274194A5234A0C55C500860D0120A619716292A3187E0B9516DB78AB1C80C62AA54DCA809D5E2400CD791F8DC44A060AB4808EAA5AEAC6D2A4316A7A41
00017419430D362E212B57EFF1E9409E23972C56D96FC355959719D6F4C2D2992B5CE4C3016E26400DA6AC82D140195868C107246B8C67C50B7BFAC04B192DDE
A080361F8ABB92B5FC8CD7020A4718A480C08F495B89BBA372C0CE9B03A35A4F8216E44088040B20808076E9F8D74002C54CE094C5DA0DC68E821C2B6163C543
42BC84C70C9887B236AF1643CDC717CBD3B2C814349CB139F3B86C3172CB21F0A67544176DF4D14827AD34751100003B}}
\par\par \b \uc2 UPDATE: \uc2 Biogen\uc2  Profit Slides as Costs Rise Ahead Of Drug  \highlight22\uc2 Launch \highlight\b0\par\par\uc2 669 \uc2 words\par \uc2 28 January 2013\par 10:39\par \uc2 Dow Jones Global News Select\par \uc2 DJON\par \uc2 English\par \uc2 (c) 2013 Dow Jones & Company, Inc.   \par \par \uc2 --\uc2 Biogen\uc2  sales and marketing costs rise 32% ahead of \b \highlight22\uc2 new drug launch\b0 \highlight\par \par \uc2 --Defends safety of BG-12, an experimental MS drug pending FDA approval\par \par \uc2 --Sales of \uc2 Biogen\uc2 's biggest drug, Avonex, rise 7%\par \par \uc2 (Adds company comment, additional details)\par \par \uc2 \f2 \par  \par    By Joseph Walker \par  \f28 \par \par \uc2 \f2 Biogen Idec Inc\f28 \uc2 \f2 .'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing MS treatment.\f28 \par \par \uc2 \f2 The company is awaiting a decision by the \f28 \uc2 \f2 U.S. Food and Drug Administration\f28 \uc2 \f2  on MS therapy BG-12, which the firm said Monday it will market under the brand name Tecfidera. \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  shares are up 23% in the past year on hopes that the oral-pill therapy could eventually generate $3 billion annually.\f28 \par \par \uc2 \f2 An FDA ruling is expected by late March, but promotional planning and increased sales force costs for an anticipated launch of Tecfidera drove up \f28 \uc2 \f2 Biogen\f28 \uc2 \f2 's selling, general and administrative costs by 32% in the fourth quarter and 21% through 2012.\f28 \par \par \uc2 \f2 The company defended the increased spending, saying the Tecfidera launch presents a unique market opportunity. The spending will continue to increase in 2013, \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  said.\f28 \par \par \uc2 \f2 For 2013, \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters had forecast $7.27 a share on a 9% rise in revenue to $5.98 billion.\f28 \par \par \uc2 \f2 The company was forced to respond Monday to concerns about the drug raised by competitor \f28 \uc2 \f2 Teva Pharmaceutical Industries Ltd\f28 \uc2 \f2 . (TEVA), which earlier this month formally asked the FDA to deny Tecfidera's approval because of the potential for kidney problems, which had been found in animal testing.\f28 \par \par \uc2 \f2 "You may have noticed there has been some noise from competitors, which is not surprising," Biogen Chief Executive \f28 \uc2 \f2 George Scangos\f28 \uc2 \f2  said. "I take the noise to be more a reflection of competitive worries about [Tecfidera] more than anything else."\f28 \par \par \uc2 \f2 Biogen\f28 \uc2 \f2  shares were recently up 3.4% at $151.17, reflecting \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  management's continued confidence in a March approval for BG-12.\f28 \par \par \uc2 \f2 Mr. Scangos said clinical trials hadn't turned up any kidney problems in humans.\f28 \par \par \uc2 \f2 The FDA's decision was delayed three months from December. \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  has downplayed the significance of the delay, saying that it doesn't necessarily signal problems with Tecfidera.\f28 \par \par \uc2 \f2 As a pill, Tecfidera is thought to be more effective and convenient than \f28 \uc2 \f2 Biogen\f28 \uc2 \f2 's current injectable drugs. Competitors, including \f28 \uc2 \f2 Sanofi SA\f28 \uc2 \f2  (SAN), brought their own pill-based drugs to market earlier, however.\f28 \par \par \uc2 \f2 Biogen\f28 \uc2 \f2 's fourth-quarter sales rose 7% to $1.4 billion, driven largely by increased revenue from MS-therapy Avonex, the firm's biggest-selling drug. Last week, \f28 \uc2 \f2 Biogen\f28 \uc2 \f2  said it completed a successful late-stage trial for a longer-acting version of Avonex, which analysts said could help the company gain market share from competitors if it is approved by the FDA.\f28 \par \par \uc2 \f2 The company reported a profit of $292.1 million, down from $300.2 million a year earlier. Profit per share rose slightly, however, to $1.23 from $1.22 a share due to fewer shares on issue in the latest quarter. Excluding certain items, per-share earnings fell to $1.40 from $1.51 and missed Wall Street estimates of $1.46 a share, according to analysts polled by Thomson Reuters.\f28 \par \par \uc2 \f2 Research and development costs rose 1.8% in the latest period as the company looks to develop new drugs for degenerative neurological diseases, including MS.\f28 \par \par \uc2 \f2 --Melodie Warner contributed to this report.\f28 \par \par \uc2 \f2 Write to Joseph Walker at joseph.walker@dowjones.com\f28 \par \par \uc2 \f2 Corrections & Amplifications\f28 \par \par \uc2 \f2 This article was corrected at 12:59 p.m. EST to correctly reflect the quarter in which \f28 \uc2 \f2 Biogen\f28 \uc2 \f2 's selling, general and administrative costs rose by 32%. The company's SG&A costs rose by 32% in the fourth quarter, not the third quarter.\f28 \par \par \uc2 \f2 Subscribe to WSJ: \f28 {\field{\*\fldinst{HYPERLINK "http://online.wsj.com?mod=djnwires"}}{\fldrslt{\cf2 \uc2 http://online.wsj.com?mod=djnwires}}}\uc2 \f2  [ 01-28-13 1039ET ]\f28 \par \par \uc2 Document DJON000020130128e91s00047\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw166\pich40\picscaley100\picscalex100\picwgoal2490\pichgoal600
47
4946383961A6002800F700002A4A9CD1D8EA95A4CE4964AAF0F2F85871B18598C6768BBF3957A3E1E5F1677EB8B3BEDCA4B1D5C2CBE3F2F4F9FBFBFDF4F6FAEC
EFF6F8F9FCC6CFE5C5CDE4E0E4F0F1F3F8F5F7FBE1E6F1D5DBEBF7F8FBD9DEEDEEF0F7DFE3F0D4DAEBE3E7F2D7DDECBFC8E1BBC5DFFDFEFEEBEEF6FBFCFDCED5
E8DBE0EEFAFAFC9DABD1AEBAD99EACD2E4E8F2F6F7FBF3F5FAE7EAF4E7EBF4D2D9EAE8EBF4C2CBE2E6E9F3AFBAD9C9D1E6AFBADAA8B5D74F69AE90A0CBCCD4E8
DADFED9FADD3E6EAF3DADFEEAFBBDAD5DBECD9DFEEA1AFD3DDE2EFEEF1F7D2D8E9EFF1F8E9ECF5F5F6FA798DC0798CC0DEE3F0BAC4DFE4E8F3DCE0EEA6B3D5D0
D6E9CBD2E791A1CC7388BFEDEFF7ABB7D73A56A3BEC7E1566EB1C2CAE3F3F5F9B7C1DED3DAEB6C81BBCCD3E7ECEEF6C1CAE2EDEFF6D3DAEA9DABD2D6DCECEFF1
F7C9D1E5C7CFE5C0C9E1FDFDFE94A3CDF5F7FAD0D7E9B7C2DE899AC8E2E6F2D1D7E9FEFFFFA5B2D5D1D7EAB0BBDAFCFDFEA7B4D6E9EDF5FAFAFDD8DEECAEBADA
ADB9D9DCE1EFCBD3E793A2CC8597C6CFD6E9FEFEFEE5E9F37D8FC298A7D0B9C3DFB6C0DDD9DFEDF9FAFCE2E7F2FEFEFFDDE2F06E83BC4E68AD8395C599A8D099
A8CF1B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000A60028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710234A1428491280041019549434
B1A3C78F204336DC38E06102001B45AA5CC9B2E5C18D920C381C00D3A5CD9B3821564429690143033B2BE61C4AB468C502052C624C18A0E2019E071148125010
C080A50207001048C022C105310502855931C04001921010207892ACA40393D0BAED3989A659AE924A0AE409536F5399939A1620D8558140B06ED53A3CDAA0A2
DE8304A4AA4D595000800200D60E4409C067D6AD93BA823E1C761250AA901128282D102DEAD079AB8ECE2AE92EECC756091EA81DB874D3BC4B0B0B5C6D3BAE01
AC0B8F9A768A70355DCA034F1A2000C0F0E60152016BC53B1B2CE0D3089F12FF006ADB3541060601CCAECB1B2FEEC793769BFD2B50B045F4C22711F7A89CFD54
831A9506DD7008B446D75E0A10905401046C075B77A58D55D16BBD5115D963E60D749C6C05D9355057B8B9E5976F530520D501F9ED8758459E31D45F5BED09D4
9662930CB8E246052228D06E0820009A685F45F89F413491855A86B771489087EE5D17180008D8465F85A125459375FB6978A08B920C465A5A9AF967DB80AA05
895A750331C0D966737D372441681587DD5A729105DF24EA159494884E3ED9597D24BE361696736D995C97040D2A5645805124D4A20D740880596846E7607C73
45BA1C859324808097038165188C30A147509EE7CDF55A6EF5A144D5944D51FFB840A50192452397A0D2566245390E34E0446A8C20D01C1A4CE2011245253B54
7FD1F124558C8E72F411059AA6D0C22487F4A1ECB636311B2A4C9CD6F8A847265030C90A124C32C5059370400106DCC61B92B703ED169B41BF3E94C20B45B831
09185D48004915246801850376C8AB7047F472251572BE8E1BD10A11B8A0C2246BB0D0E92417C06B43064414B7F0C80A355C5F8B05E5EBD00E1784F145428A10
E0800B24D75C32A211A9ACD0106F4C42080B1F20B2D00651741081CD481364F2A1D23EF444069380E083430F38F040D258C7DB861891185210014F6D7480591A
5470421E59A73DD42293340275410D58656A00AB51F580CC6AE7ED92145724FF314919570F142B800310C086057A27BE9205224CF2400E4E1054C09D8A577E93
17637C2D89A909BD55D0B3380E4716467B6EA4A9AF705104579DCC597ED31233C00DED4BA9CBF8265A0221903AD86615D0AB407BA2E7B9EA7149B2D401B9BAAE
D2237F4C62441604352632BEB5777ABBB4A5571469E99C2B5DBBE7AC0FAFFC4A85DC31090C67106628ED6C5D1FDA014B25B0F924BE97FCFDEAC68F9F93155418
8414D3CA011DAF724796ED15B04364410F5A20A63F96FC40041598004106571006146E1212085C033778101EEC61127A2083EC06A0A90024852A1DA8000438C8
C2826001102388C14112602FA7DCC5021C58610B7728101438C20C359020437F98D0010E2482873C14C4B542F0818540C0015044221241A0043900210411E8C1
41503089137840088390220F4BB085496C000E1AA043095E80864EADA50E7138820EC528451AF061123A500104FC10810098400651C3C006E828C60FDC601224
F0800402C185493062026920A424078283209CAF0902C1C32437C949960404003B}}
\par\par \b \uc2 AdvanDx \highlight22\uc2 Launches \highlight\uc2  Enterococcus QuickFISH BC Molecular Diagnostic Test\b0\par\par\uc2 729 \uc2 words\par \uc2 15 January 2013\par \uc2 Manufacturing Close-Up\par \uc2 MFGCLU\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 AdvanDx, Inc\uc2 . announced the commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  of Enterococcus QuickFISH BC, a new rapid molecular diagnostic test that identifies potentially life threatening bloodstream infections caused by Enterococcus.\par \par \uc2 According to a release, this new QuickFISH assay is immediately available and complements the September 2012 \b \highlight22\uc2 launch\b0 \highlight\uc2  of Staphylococcus QuickFISH BC for the identification of Staphylococcus aureus and coagulase-negative staphylococci. With these \b \highlight22\uc2 new products\b0 \highlight\uc2 , QuickFISH can now be used to identify the causative pathogens of approximately 70 percent (Ann Clin Microbiol Antimicrob. 2004 May 10;3:7) of hospital acquired infections from blood cultures.\par \par \uc2 Enterococcus species are the fourth most \uc2 common cause\uc2  of hospital-acquired bacteremia in the U.S. and fifth most common in Europe. The majority of enteroccocal infections are caused by Enterococcus faecalis and Enterococcus faecium. Treatment decisions are difficult because these species exhibit differing antibiotic resistance profiles. While E. faecalis is generally susceptible to ampicillin, infections caused by other enterococci, mainly E. faecium, are often resistant to ampicillin or vancomycin, or both. Conventional identification methods can take up to 3 days or longer, and patients withE. faecium bloodstream infections often receive inappropriate antimicrobial therapy for days, leading to higher mortality and significant hospital costs. With this new test, clinicians may prescribe earlier and more appropriate therapy for enterococcal infections. QuickFISH marks a significant advance in time-to-result and ease-of-use that will help clinicians, hospital pharmacists and clinical microbiologists optimize antibiotic therapy much earlier for patients with bloodstream infections.\par \par \uc2 QuickFISH is a new, rapid, molecular diagnostic platform developed by \uc2 AdvanDx\uc2  based on its clinical proprietary PNA technology. The new platform enables (20 minute) species identification of bacteria directly from positive blood cultures allowing the reporting of pathogen identification at the same time as the reporting of Gram stain results.\par \par \uc2 AdvanDx\uc2  believes the speed and ease-of-use of QuickFISH within the microbiology lab will provide positive clinical and financial benefit to patients, health care providers and institutions by enabling more targeted antibiotic therapy. "The unmatched speed and simplicity of the QuickFISH procedure, which allows the laboratory to report pathogen identification to clinicians with the Critical Value Gram stain result, provides a much greater ability to optimize therapy within half an hour of receiving a positive blood culture." said \uc2 Jim Coull, Ph.D\uc2 , Chief Technology Officer for \uc2 AdvanDx\uc2 . "Until this year, the ability to provide pathogen identification in 20 minutes or less from a positive blood culture was not possible. QuickFISH is specifically designed to address laboratory workflow needs while assuring that clinicians receive the critical information that enables them to best optimize antibiotic therapy. We believe QuickFISH is a major advance for patients and their health care providers and when combined with a sound antimicrobial stewardship program, will provide the quickest and most appropriate therapy for the patient."\par \par \uc2 As noted in an article by Debra A. Goff, PharmD, FCCP in the August issue of Pharmacy Practice News, "During the past decade, the prevalence of ASPs (antimicrobial stewardship programs) at US hospitals has greatly increased, and the state of California now mandates that general acute care hospitals develop a program to evaluate the judicious use of antibiotics. Additionally, the Infectious Diseases Society of America (IDSA) has made recommendations to the \uc2 Centers for Medicare & Medicaid Services\uc2  (CMS) to require stewardship in all acute care hospitals in the United States as part of infection control." It goes on to state "The goal of antimicrobial stewardship is to optimize antimicrobial therapy for improved patient outcomes, with maximal effect on subsequent development of resistance". \uc2 AdvanDx\uc2  believes QuickFISH, when combined with stewardship, can provide the most accurate and timely therapy to assist with meeting the above goals.\par \par \uc2 QuickFISH assays for use with gram-negative rods and Candida species from positive blood cultures are currently in development for launch in 2013 following regulatory approval. \uc2 AdvanDx\uc2  has submitted the 510(k) application for the thirdQuickFISH assay for rapid identification of Escherichia coli, Klebsiella pneumonia, and Pseudomonas aeruginosa from gram-negative pathogen blood cultures.\par \par \uc2 AdvanDx\uc2  is a provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients.\par \par \uc2 Critical Values are laboratory results that indicate a condition likely to have significant medical implications for the patient requiring immediate clinical intervention.\par \par \uc2 Complete details:\par \par {\field{\*\fldinst{HYPERLINK "http://www.AdvanDx.com"}}{\fldrslt{\cf2 \uc2 http://www.AdvanDx.com}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document MFGCLU0020130115e91f0000w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw35\pich40\picscaley100\picscalex100\picwgoal525\pichgoal600
47
494638396123002800F70000FFFFFFFFF9F9FF322EFF2B27FF2924FF3C39FFF6F6FFDDDC3333331010108383833636360E0E0E0000000D0D0D32323282828213
13133434343030300B0B0B3B3B3B2D2D2D2A2A2A1F1F1F2222222121211D1D1DF5F5F59090903131317272723838383939391111112F2F2F050505F4F4F40C0C
0C1919191414147575752C2C2CF7F7F7949494C8C8C89696964F4F4F6E6E6EDCDCDC0F0F0F4545452323231B1B1B1212121A1A1A1C1C1C999999060606181818
7D7D7DFCFCFCBEBEBEC2C2C2979797F2F2F2F3F3F33535352E2E2E919191151515BFBFBFB4B4B42424242B2B2B4E4E4E3A3A3A7878781E1E1EBABABA8F8F8FFF
DAD9959595B7B7B7B8B8B8FF3632FF342F090909202020262626A9A9A9FFE0DFFFFCFC505050B5B5B59C9C9C6464648B8B8BAEAEAEEEEEEEFF39340A0A0A3D3D
3D484848E8E8E8929292535353A0A0A07B7B7B9D9D9D8C8C8C8E8E8E080808FFFAFAFF4A47C4C4C4D4D4D48888889B9B9BD8D8D89F9F9FFF4743B6B6B6C7C7C7
B1B1B10303038585855C5C5CFFF8F8070707656565767676666666BBBBBB616161777777FCFFFF404040D3D3D3FFFBFBFF39357F7F7FFFF8F7FFE2E1FFF1F1E2
E2E26D6D6DFFF4F4989898282828676767292929B2B2B2737373707070F1F1F1FFD7D6464646EFEFEFFF403C7979798686868787873E3E3EA4A4A41616167C7C
7C000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A31384139344338393530463031314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3138
413934433841353046303131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3138413934433837353046303131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3138413934433838353046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000002300280040
08FF0027710940B0A0C18308131604002900808710234A9C4851A2018710F54440508A108033181E44980251410204092044848142820C180000391CB320C908
1C8A001C69D122128B1A0892800020E564CA8A0F2F225DCA14A2D2A650293E8558A282060458B1985911D12482092166CCB810C143880817840098FAC1C1020A
4000FC8861E98404071F1E7A4D500480920614188CFAE11463D4C349AB0C58CCB8B1E3C7901D33328C38EAD4CA502F3FF4D14087031D0D8E4894D4808169D326
1860F873A7B0C4146E1F4C98B0C0C1A0AE46554234B4430283BC8E0C070991C142063A009E187990A14209BD46DD0068C2C4C805263534A0598B918F080437BA
00FF38144885050F121088F00260AFEE8A061601F063E1C588B81321207841648D98074B4C90C6529A6146206506125880000C36E8E0831046F8E0270826085F
85164E5460861661C8A16B12714009142E409103071215C243072C76F0060B5AC4D0E1444D38909E0426802291570BA8808106974860011C11CC9114825444F0
80071720F0000A4FE0A65E230F05C1C30D0F2C40821DDC455455064A7492C3041E6850018AD0A1F41E00A2C880000A82004050446DBDE502006C98505B0A25E5
06111E4E8CA0250B5D3E84840D08ECA006444B6CF0800D48A4C917002A5C81C010119080C9910F6D02020D4460C0410B0D9C401B023480A0D65E6100600A1875
F86FD043444F69C2C05B5F00904519389CE0C4A50C640240287E22A514290D6CD0472213795209051B34B0471BC936C0A7B17120C255542BCC9A99871F161AAE
86E07E6840145B1CA0EEBAECB6EBEEBBEB3EC2891504D46BEFBDF8E6AB2FBE64E421400100072CF0C004171CB000720404003B}}
\par\par \b \uc2 Santarus gets marketing approval for bowel disease drug and gives strong 2013 forecast\b0\par\par\uc2 321 \uc2 words\par \uc2 15 January 2013\par 15:33\par \uc2 Associated Press Newswires\par \uc2 APRS\par \uc2 English\par \uc2 (c) 2013.  The Associated Press.  All Rights Reserved.   \par \par \uc2 NEW YORK (AP) - Shares of \uc2 Santarus Inc\uc2 . climbed Tuesday after the company received marketing approval for a \b \highlight22\uc2 new drug\b0 \highlight\uc2  and issued a strong sales outlook for 2013.\par \par \uc2 THE SPARK: The company said Monday that the \uc2 Food and Drug Administration\uc2  approved its drug Uceris, which is intended to put symptoms of ulcerative colitis, an inflammatory bowel disease, into remission. Santarus plans to \b \highlight22\uc2 launch\b0 \highlight\uc2  the drug in March.\par \par \uc2 THE BIG PICTURE: The company said it should meet or surpass its previous guidance in 2012, and its revenue outlook for 2013 was better than analysts had expected.\par \par \uc2 The San Diego company had forecast net income of $12 million to $14 million and $210 million in revenue for 2012. FactSet says analysts had projected net income of $14.2 million, or 20 cents per share, and $209.3 million in revenue.\par \par \uc2 In 2013 Santarus expects net income of $50 million to $54 million and revenue of $320 million to $325 million. Analysts had expected income of $54 million, or 76 cents per share, and $301.3 million in revenue on average.\par \par \uc2 Santarus also makes the acid reflux drug Zegerid. It is not currently marketing Zegerid, but is getting ready to resume sales because of a favorable court ruling regarding the patents on the drug.\par \par \uc2 THE ANALYSIS: Santarus should have a good year in 2013, said Roth Capital Markets analyst \uc2 Scott Henry\uc2 , who has a "Buy" rating on the company's shares. He said Uceris was a key drug for the company, and was optimistic about Santarus bringing Zegerid back to market and filing for marketing approval of a new drug.\par \par \uc2 SHARE ACTION: Santarus stock rose $1.26, or 11 percent, to $12.54 in late afternoon trading. The shares are up more than 80 percent since the end of August and have nearly tripled in value of the last 12 months.\par \par \uc2 7\par \par \uc2 Document APRS000020130115e91f003a3\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Dilantin(R) Chewable Tablets\b0\par\par\uc2 389 \uc2 words\par \uc2 14 January 2013\par \uc2 Pharma Business Week\par \uc2 PHBW\par 45\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2013 Pharma Business Week via NewsRx.com    \par \par \uc2 2013 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) announced that its subsidiary \uc2 Mylan Pharmaceuticals Inc\uc2 . has received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of \uc2 Pfizer\uc2 's Dilantin(R) Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments\par \par \uc2 Phenytoin Chewable Tablets USP, 50 mg, had U.S. sales of approximately $16.5 million for the 12 months ending Sept. 30, 2012, according to \uc2 IMS Health\uc2 . Mylan is shipping this product immediately.\par \par \uc2 Currently, Mylan has 185 ANDAs pending FDA approval representing $80.6 billion in annual sales, according to \uc2 IMS Health\uc2 . Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Mylan Inc\uc2 ., Government Agencies, Offices and Entities.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC\par \par \uc2 Document PHBW000020130111e91e00012\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw158\pich40\picscaley100\picscalex100\picwgoal2370\pichgoal600
47
49463839619E002800F70000D1D8EA677EB895A4CE5871B1F0F2F82A4A9C4964AA768BBFB3BEDCC2CBE3E1E5F18598C63957A3A4B1D5F2F4F9FBFBFDF8F9FCEE
F0F7F4F6FAECEFF6DFE3F0E0E4F0F6F7FBDBE0EEE2E6F1DDE2EF9EACD2FEFEFFFEFFFFD9DEEDACB8D8A6B3D5E0E5F1FDFEFEDCE1EFF5F7FAE8EBF4F5F6FAF3F5
F9E4E8F2C6CEE4E5E9F3E1E6F1EAEDF5FCFDFE9FADD3C2CAE3D8DEEDD0D7E9C3CCE3D4DAEBF1F3F8D5DBEB9DABD1B6C1DDAAB6D8C9D1E66F84BDABB7D7FAFAFD
C4CDE4F3F5FAB2BDDA4E68ADB5C0DDFAFAFCFAFBFD92A2CC8E9ECAE4E8F37085BE3855A4E8ECF4FCFDFDEDF0F7ADB9D9BBC4DFB9C3DECAD2E6CCD4E8D2D8EACF
D6E9EBEEF59BAAD0D9DFEECDD5E8D2D8E9B0BBD9E9EDF58697C7EDEFF6D6DCECC6CEE5C6CFE5F2F3F9A3B1D4E9ECF5ECEFF7D1D7E9FDFDFE96A5CEDBE0EDF5F7
FBD0D6E9BCC6E0F9FAFC7E91C35069AEB1BCDA94A4CDF4F5FAC5CDE4B6C0DD7B8DC1E2E7F2536CB0CBD3E7BAC4DFECEEF699A8D0D3D9EABFC8E1FBFCFDB8C2DE
AEB9D9D6DCEB8295C5C0C9E1D0D7E8BEC7E0B2BDDBD2D9EADADFEE8798C7F7F8FBC7CFE4D7DDECD3D9EB6F84BCC1CAE2DFE4F19BA9D1778AC0A6B3D6D3DAEAE7
EAF41B3D95FFFFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C000000009E0028000008FF0027091C48B0A0C18308132A5CC8B0A1C38710232E9444B1A2C58B150748DCC8
B1A3C78F10318ABCA811A4C9932853221CC9525249953063CA7C5831C1CC9B387386A4685362800208082E900460528091042619C05840A000910D8C2225C840
928082050C0804E09220014901B6822DD840D2028108445EE5FA72D2D7B05C459E555873E351AB0387161DC8352CC1A57B0B3E0D2A50C158BE870517185020E9
C0AC6225195020F06DE4AB5B0B98459B9860DCC9953B4B0D3C91A7DDC52E93EAF52C1AF0C1C1030DFB153B3B768105040AD4863C89ADA402512DF79654353883
019B27A5AD8D183970B7A28F92A6DBB26BC29F930E1007B01A31F3A515E73AFF85CA9AB95106E3094FE2CD550080AA07847345C0388101035CE7A6B5E878B87B
F8C20D249D43D5598710769394251951E515E49A41B01D7580417D15B49F45E809C41E5E0420B7945FF3115055010AE4C79979FEB9E561740C3654605B0621D8
1B78A455F8578B824942D85130DA381003B5A585D986984D32D461F34DA20050C3E9279A58451EC9DC802E9AE65353042157636B2225059B403C06E6637692F4
349001051445244108E826967A623989D159EDB1E92641543254974E028D1182401F5830090D48F069684A7BF289421E02D560C6247B5C70E8A42025AA130C31
4CD28221930CE1C62411705101A5A44664E94C1A1441001093D8010904774CFF10860B1F38C042A9B85659A64E2DAC3082079390818192935800C22438D090C1
74B9362B50812279F44409313891901C0438D083B3DC0E042D461B3D92C5246A6070C20B0B757006051374EBECB7176D94011E93BC9082430F38F080BBFCDE04
801435D8501001076846D101454150C1053BF4EB304A1B4C6284150625905554BD1D75D503D93EECB147511C61C2245B08C15A91033560000123CCF0F1CB1B79
C1C42449ACA142965AC1AC734A8A0032B024182724C98404195C5186C8594459D2A70EEDED844F5944F4CE1FC511484109E0B8D2D44AE2359E400C104D705103
643850D25139FD2CD49250961D8C544754081193F431074159335B90DA8579FF3DC95302316D1AD34113C4B7D35157C475DC1135F2C5242B1CE2958E13716D58
918013ECB66151954DD7D488B7CDF84957E460D00070EF6D91464653849E8817D924F8AE375A14D5536E8FFE51064D28C0C3C906A99C1404FBEA6EBC084B4C52
C614584BD61300C85D45410512186FBC0B7E843048C40529A09DE27BCD1041F5D61BFFC00F5AF8F04643145010411AE51BCF81A08BE48E90040EE41FBFF58438
C28120685082060E12844988400654B8D7FE74C782915D00041080811E488082496020296C10C3F816B83F1200AB0D3A28011D2600852A446212885041073818
BF13F06112139001040000874930A20B7F60A10E277183444C020C75100816077648C4229A2420003B}}
\par\par \b \uc2 Illumina  \highlight22\uc2 Introduces New Products \highlight\uc2  for Sequencing Ecosystem\b0\par\par\uc2 855 \uc2 words\par \uc2 11 January 2013\par \uc2 Entertainment Close-Up\par \uc2 ENTCUP\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Illumina announced a series of product and technology solutions for its sequencing ecosystem - from sample preparation to system enhancements to data analysis -- that will enable the next discoveries in understanding the genome.\par \par \uc2 "Illumina has consistently led the market in conceptualizing, developing, and executing on industry-changing sequencing technology, and we continue to provide scientific advances that facilitate fully integrated and highly economical sequencing with very rapid turnaround," said \uc2 Jay Flatley\uc2 , President and Chief Executive Officer of Illumina. "These capabilities allow us to continue to meet the evolving needs of our customers, as they develop an ever-increasing range of applications, in new and emerging markets from agrigenomics to molecular diagnostics."\par \par \uc2 Illumina said that accelerating the sample prep process is fundamental to improving sequencing workflows and decreasing turnaround time, a factor for sequencing to be adopted in clinical settings. Illumina announced and previewed several solutions in sample preparation technology:\par \par \uc2 -Nextera Rapid Capture Exome Kits represent a new generation of targeted enrichment products, providing exome enrichment workflow on both the HiSeq 2500 and the MiSeq. With a sample-to-data protocol of less than three days, the kits deliver a 70 percent speed improvement over current technologies, with a solution optimized for efficient enrichment of coding content. Commercial availability for these kits is scheduled for the end of 1Q'13.\par \par \uc2 -Nextera Rapid Capture Custom Kits enable enrichment of hundreds of kilobases to tens of megabases of custom-selected content. Fully automated probe design through DesignStudio and the ability to add content to previously designed panels will be provided. Nextera Rapid Capture Custom Kits will begin shipping in 2Q'13.\par \par \uc2 -TruSeq DNA PCR-Free Kits are a simple, all-inclusive sample prep solution for whole-genome sequencing providing industry-best genome coverage, the ability to sequence the most challenging regions, and the power to identify variants with high accuracy. These kits will be available to order on January 21, 2013.\par \par \uc2 -Nextera Mate-Pair Sample Preparation Kits offer a gel-free method for preparing up to 15 kb mate-pair libraries in less than two days with the industry's lowest DNA input; an ideal approach for de novo sequencing, genome finishing, and the detection of structural variation - even in the most complex genomes such as those derived from cancer. These kits are available for immediate order.\par \par \uc2 -TruSeq Targeted RNA Kits bring a new standard to mid-plex gene expression profiling and validation by overcoming significant challenges in cost and workflow. User-defined custom panels of 12-1,000 assays can be created to target genes, isoforms, splice junctions, and cSNPs, all of which can be added to a variety of pre-selected gene panels focused on cell pathways and disease states. Commercial availability for the TruSeq Targeted RNA Kit is scheduled for 1Q'13.\par \par \uc2 Illumina also highlighted a number of core sequencing platform enhancements that will increase the throughput, read lengths, and speed of existing systems, as well as decrease running costs.\par \par \uc2 -A new flow cell technology will provide a significant increase in cluster density and number of reads per flow cell while reducing image-processing time. This new technology influences support for counting applications, lowers the cost per data point, and affects turnaround time for sequencing projects. First customer experience with these new flow cells will occur in the second half of this year.\par \par \uc2 -A novel library prep method and analysis algorithm, enabled by the acquisition of Moleculo Inc., will produce synthetic read lengths up to 10 kb at an extremely low error rate (Q50 or better). This advancement allows more coverage and accurate genotyping of genes and new applications such as phased resequencing of human genomes, and rapid de novo sequencing of complex plant and animal genomes.\par \par \uc2 -HiSeq 2500 chemistry enhancements enable the industry's highest daily throughput and drive down the price of whole-genome sequencing. With support of paired 250 base pair read lengths in rapid run mode, the HiSeq 2500 will be capable of generating up to 300 Gb in rapid mode with sample to data in less than three days. These enhancements will be available in the second half of this year.\par \par \uc2 Illumina also shared a development in the evolution of its cloud-based data analysis, storage, and sharing platform, BaseSpace:\par \par \uc2 -BaseSpace Apps, a dedicated applications store for BaseSpace, has become a seminal environment for the deployment of informatics tools. The community has grown to more than 100 independent developers who are working to bring an assortment of analysis tools to a cloud-enabled user base.\par \par \uc2 "Our ability to rapidly innovate across the entire workflow of next-generation sequencing ensures we are better positioned than ever to continue creating and delivering value to both our research and clinical customers," said \uc2 Christian Henry\uc2 , Senior Vice President and General Manager of Illumina's \uc2 Genomic Solutions\uc2  business. "With enhancements to our platform, we continue to set the standard for speed, accuracy, output, and workflow."\par \par \uc2 Illumina is a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function.\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document ENTCUP0020130111e91b00010\par }\page {\par\fs20\b \uc2 Teleflex \highlight22\uc2 launches \highlight\uc2  Babi.Plus respiratory product\b0\par\par\uc2 John George   \par \uc2 100 \uc2 words\par \uc2 7 January 2013\par \uc2 Philadelphia Business Journal Online\par \uc2 PHIBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2013 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 Teleflex Inc\uc2 . expanded its Hudson \uc2 RCI\uc2  respiratory product line Monday with the {\field{\*\fldinst{HYPERLINK "http://finance.yahoo.com/news/teleflex-introduces-respiratory-solution-critical-120000206.html"}}{\fldrslt{\cf2 \uc2  addition of the Babi.Plus Bubble PAP Valve.}}}\par \par \uc2 The \b \highlight22\uc2 new product\b0 \highlight\uc2  from the Limerick, Pa., medical-device company was developed to apply positive airway pressure to critical-care infants.\par \par \uc2 Other respiratory products marketed by \uc2 Teleflex\uc2  (NYSE:TFX) include the Hudson \uc2 RCI\uc2  Infant Nasal CPAP Cannula System and the ConchaTherm Neptune Heated Humidifier.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=philadelphia&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Philadelphia Business Journal for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PHIBJO0020130107e9170002v\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw115\pich40\picscaley100\picscalex100\picwgoal1725\pichgoal600
47
494638396173002800F7FF009047113B2114DB9540FA5E0BFE720DD26233393939FC6C0CFFC767B3B3B3893A07242424FFA32A828282ABABACFFFEC3FD8010F2
F2F2FC7C10FEC67BFEDAA1D2D2D28E5A23FFFBB1FFAA33D3923E2E1809939393E5E5E5C4C4C5A4A4A4161616FF7B0DF867286B6B6B7A7A7A727272E9E9EAFFFF
FFCDCDCE5A5A5AFF8A12FFB656F8F8F8FB932AFFC358525252B24D09FD9535FFAB43B46416D6720FEEEEEEFF9413FFC347E2E2E24A4A4AFC4601000000D5D5D6
FF712DF6F6F6DDDDDEFF8A35FFDA7BCCBD78FEE3B5D5580AFFFE92FDBD6C414141BCBCBCF6AC54D8D8D8B5570B8D8D8DB8B8B8FFD483C8C8C8FFAF21C65B0BC1
C1C2F98F29FA5408B1562B6448263F2915FFB141FFCF65FFFDA5CAAE799D9D9D552404616161EC83340E0D0D683409BD8C4AFF9D2EFFEB95FFA31AFA5808FFCC
7EA99865FF5D03FFCC72FF9D1EF36C0D743708140902A96927421D03FFE8A78563379C4408FE640B3B464FFFD679FF5405FC881AFFBB44F1A347E9670DFED394
FF8310989899666666FF6809FF5807FFFFCAB37B374A2204888888EC9C44FFE6B99A6A2C866C47FD770FF86F0EFFD14CFFBA37FA670C412F1BFFC36FFF921CFD
600AEDB263EB852BFA5B23726341794A19FCFCFDFF9B14FF6819FA630B612D054E3A1D2D2E2FFFD59EA37531FEDEB2FF7F2AEB9136F57D111E0F05FEDAA96B4F
2BFCB669F6861AFFB54B542A19F95107FFD080FA4F03FF7032FFBE60FF5306F4680C050403333B41ED7C34823E230A0807FDCD87F3F3F4DFDFE0EBEBECE3E3E4
FAFAFBFA861ACBCBCBFDFDFEBF772B742F059D753DF0F0F0EF7D10E4A356F7CA77182630040B13F37C10FFB924E6D38A9F9FA0D6AD72DAB57ECA9C5BFF5B09C3
863BED8112FFC0368F8F8FFFD058EDB973F6D39CFF5E17595032E8E8E8E05F0CE3C390D3D3D4FFEFB8DADADBBDA278A9500AF3760FFF6F1F495A67FFD378BFBF
BFFFD86F6651317C5A2BD0D0D0AE712F512F0FC36030FDCE8BF9640CD4A656FFCB81BF5109E6790FFF640B713A207A5C30FCB45FE16A2FD05009956E3AC2A67B
FFDD94FA5702969697FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A31413938414139323530463031314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3141
393841413933353046303131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3141323741443837353046303131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3141323741443838353046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000007300280040
08FF00FF091C48B0A0C1830813123CD2A5D3978710234A9C48B122C4052E3C28DCF845873913B96CC9EAA843872C034B701174E0E243C9920B487CFB87C2804D
03460C90D4F105C50659B224359940B4A8D1A24D9EC541648DD5D109665899795A34AA54A3AC58C54B634547820A7E16BC8429A203C18E1E7E45B135F665035E
DD0C78C87502D78ABB7887DD303142C7865F275C8EEDD243D72C1D93524880202105A64D25C190510CA1861293A36ABCD1B1A90684CF1052246BA303009919A4
74BC91318FD80C002535D4E003414CD74E3B4C98A061CE1F099FDA74E1D041ED5F171C393B2DF8F085ADAD055D1214DCD1C0C807A01F8C10E2F06F4497EFE0C3
7FFF4761121F8148F4E6A85FCF9E9E264DE9DFCF89FFBEBEA6F9045E941C2447DE9021F9BCA0001725054340281AE83002090BC8C2930122F8215E177E6C64E1
85180E634E033A9042490E39F05040823AB8B0C58928A6A8E28A2B32C11D8607B555D20930D668904B568CF1802142F4E8E38FA0781348208680F2E3914826F9
E303599852920F3576C484091180D4800B3834B08B6E2590E4806E4CB8D08901246C69820B257960822E26EC40020E2E4CF9CB2E0E16924A0C6E58A0A79E871C
C2960E165423880EB6E4D14257B17D9241069FA4A6431ED5AC53123BD1082040068738D846A531A4D2951FBA71208201638EB0E50A2E39F04F47D49C90803649
10FF82020A0D74A08E0F7DBCE4C72EDF1C2182114690D0C13725745152033E2420D84B2E24A1CE615E4800021B25910285122F64ABAD38F298B4061F9B6D0201
018A949BC81AA42950831C32BED4C61B728040000CA41C934B074CA030260A5BD0F08D032718A1431F3616BC1187A5FD300E34B034BCCA141047DC0A2C76546C
F1C5185B4CB11D80740C48C58064F2433B251961F0C92827E4844925196056CA30C72CF34147BC94CD195AE4ACF3CE3CF7ECF3CF3A9F51C99F0D148C160D1DB0
95CBCC0A19A0833D5978B2C7D454573DF5058894E40C1C5677EDF5D77B7892451826A984614751B4A9030A2E465042074B08B685C03A8890C00D3DE0A20E3374
3BFF28820784E88043DBDA98632CA17920F04A1C5534EEF8E355DC534C15A6DC8300E3619C230C27A47C114015616071CF3DAF9C1346150190D286069CE8038F
295F688000028896E8403711AC40833A1E0CA7C3160275F4A53AED7EA0CD2FC46F60823662D9E23C5B2398804B27BF9BE0838C229870091D3A8822060BE0B320
050318B05392258C8881810C26498141003AB093BE14E07FCF96058C24E8C634F4D7CFC0FD186001066A07131CF861044B4840092E81A625AC6A60BA308783DA
B2801D70C0010AC24512963516A094841034880207D7C6011F408B0F89E0430DC05092CEA05002304CC16564218E14844B313094001FC4411AD32840078300C0
20FF54470A2E842305294884B460D0063AE02217081B0B0A68E0038115A7233878930E3E2082066C600923F0DD02D4E1879274A28B1BD8400344201696050B05
7F7AC91945701D5A40E0056FC8A31EF798C7216CE30D8388452282F1060524E2008D48240162C1853740A15B6D90C31A62A1876DFC471EE118840EDA70001838
A26423A0863F084102817D800422A0DE0756C0341BF525003F88443F0640CB5ADAF296B8CCE500CA10893FE44301436C833035C00505E4E30F68F8413D746080
563AD3207D2989E702A08A10C0A215ADC801204241052B04E09BE00CA738C7394E47958817CF4CA7CA3AE40A7CC04F074680923AE749CF8274608B4CA8A73EEB
59FF01DFB5EB9F000D28403B219D8255401D084D680FF67982923822080F08C403264AD18A5AF4A218CD284525BA0C7494C41F3672902C4432237D7A8027C6B8
402928C0D296BA940270E00638F6718D97DAF4A638A54029BC31864F76214A3A70C29A44D2816E1CC1092F3A480FD471840E2C4D21B838C151752190923C630C
EEB88556B7CA55AD66A1122569C618BA4AD6B29A55ABFC7804698E30101F74E0A84F2D48473AB0A697D882392FF9803AFE71097FCAE2031C24C44EC672D79D8C
14096928423980C0D8C63A1608A728071188F088C802210D8F00421D1E51843468B608A0052D63315B8447D441B3402882241E91864F522FAF7875CB403A7204
13FF542001BAC9AD6EB4F15A93E056B7B915C14BE88A0BE501D704E4B145215AF00A81EA4005D1280912B0909A0070A25D82C002125A900E8192E215872AC912
8E9B5BF2E860180FC4ED30B63058BD5EC2041C32826E4E3A960F6CA9A13A60860956C08C0996C409BC3001F5448101185C010F08C6830D166181F3D9000F6E30
8981DF69892BD8E00A575804304AE28645988F1D088E410C32BC615988C2066288415796500127F4B624D133C1701C283C1374C0BF63E9C32F92B0000FECCE1C
4E08B2903BE0031318CB1F2650C708BBF00B5C706F1290B883947B010935B050076C6000247AA106F6C902156AD88C64A42C6548A0A287CA30DF20D440064854
F9FF09ECD3810CD47007DB9444167E70402E741BD5080CE78AF9ED0113FEE90F1A38E103853EC24D16BD800574C2254BE8C1A1DB32450E1C2631315C6149D850
03CA5466869909976740239A1E62A2069A6C9706A44119186800191518463746D009FFA260051CF8F30337B0035F38C069723447053880A60AF6AA8D2DF3850F
2AE0920670E0082344412E92002D69A500323A50002652C0876E773B05E1308922C0C5193E10E0DC040001BA7420871AA4860B33B89612A0A00709240204289C
571BC8514212B405070EF0C50EACF8400FF082254770DB2E6E90841D2C218E3AE882137251021FF8A0E21D4053493670095F2C191786D1012D52C02E81CA631B
25FF890504523308081CE0E50748442C4AA2AE1F12AA0D387E091B40F0834F25210937D8810F22C0810610621734401321FEE1DC92E08095DD01A82D0801F180
7E811607F803BAB7CEF53F689D008D78C7B90FF08E4426B2ECE786008134C0871480E0EDF84EC1BA36F9879E37FD253830082F22A08B1B946023B8DE05D46B24
162A846296BA4CBCE2691909020443A09BF84322F051925F08441B3730DB3E61C4819200E007D068C514CA40FAD29BFEF4A84F7D1900418F3FD0031A80280334
7A894C3B8482643A50D5E6617638555021043C087E085641FC5560731CC14FBEF297CFFCE6F32004ED58A60E3A81CEDDCBCC097E18AC354194095748FFEE7797
052FC0ADAF4E5D748812D870452D4A620B8D90FFFD275B990600F02707C2FFFE06F3C54B4880FFFE1B2C4CE8E57F161210003B}}
\par\par \b \uc2 UPDATE: Accuray Announces Restructuring, Cutting Jobs by ~13%\b0\par\par\uc2 Paul Quintaro   \par \uc2 364 \uc2 words\par \uc2 3 January 2013\par 16:13\par \uc2 Benzinga.com\par \uc2 BNZNGA\par \uc2 English\par \uc2 Copyright 2013. Benzinga.com   \par \par \uc2 From Accuray (NASDAQ: {\field{\*\fldinst{HYPERLINK "http://www.benzinga.com/stock/aray#NASDAQ"}}{\fldrslt{\cf2 \uc2 ARAY}}}\uc2 ) press release:\par \par \uc2 The second fiscal quarterly results reflect a shortfall relative toexpectations, which is attributable to challenges faced in two primary areasof the business: (1) manufacturing and supply related issues, which delayedcontribution from \b \highlight22\uc2 new products launched\b0 \highlight\uc2  at the 2012 Annual Meeting of theAmerican Society for Radiation Oncology (ASTRO), and (2) commercial focus andsalesforce transitional issues.\par \par \uc2 Accuray is announcing a restructuring of operations to focus on improvingcommercial execution and position the company to support sustainable revenuegrowth and profitability. Through the restructuring, management isestablishing a cost structure that will reallocate resources\u160\'00\'A0to commercialsales and marketing initiatives and improved business processes to supportaccelerated revenue growth. The restructuring is expected to reduce staffingby approximately 13 percent and is most heavily concentrated in the UnitedStates.\par \par \uc2 As a result of the restructuring, Accuray expects to take a non-recurringcharge of $3 million to $4 million in the third quarter fiscal 2013. Thecompany expects operating expense savings of approximately $40 million peryear compared to fiscal 2012, with initial impact benefitting fourth quarterfiscal 2013 results.\par \par \uc2 "In my first 90 days at Accuray, I have spent considerable time evaluating thestrategic and operational activities at the company, and have found manyreasons to be highly enthusiastic and confident in the future prospects andsuccess of the company. We have truly differentiated technologies in our twoprimary product platforms and a loyal installed base of customers. Our newsystems introduced at ASTRO expand the treatable patient population, increaseaccuracy, and improve throughput \u8211\'20\'13 creating economic value for our radiationoncology customers and clinical benefit for patients," said \uc2 Joshua Levine\uc2 ,President and Chief Executive Officer of Accuray.\par \par \uc2 "However, we have identified challenges that have pressured resultsoperationally and distinct areas that require improvement \u8211\'20\'13 and we have aclearly defined path to address these. As such, we are initiating a strategictransformation at Accuray in order to drive consistent performance that isrequired to create value to our customers and shareholders over the longterm," said Levine. "Through the restructuring we announced today, we areestablishing a cost structure to support sustainable revenue growth andprofitability through commercial execution, service excellence and improvedbusiness processes."\par \par \uc2 (c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.\par \par \uc2 Document BNZNGA0020130103e91300105\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  First Generic Maxalt MLT(R) Tablets\b0\par\par\uc2 539 \uc2 words\par \uc2 2 January 2013\par 10:24\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2013  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par - Company also launching immediate-release version Maxalt(R) Tablets - \par  \f28 \par \par \uc2 \f2 PITTSBURGH, Jan. 2, 2013 /PRNewswire/ -- \f28 \uc2 \f2 Mylan Inc\f28 \uc2 \f2 . (Nasdaq: MYL) today announced that its subsidiary \f28 \uc2 \f2 Mylan Pharmaceuticals\f28 \uc2 \f2  has received final approval from the \f28 \uc2 \f2 U.S. Food and Drug Administration\f28 \uc2 \f2  (FDA) for its Abbreviated \f28 \b \highlight22\uc2 \f2 New Drug\f28 \b0 \highlight\uc2 \f2  Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base). These products are the generic versions of Merck's Maxalt MLT(R) Tablets and Maxalt(R) Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.\f28 \par \par \uc2 Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and was awarded 180 days of marketing exclusivity.\par \par \uc2 Mylan CEO \uc2 Heather Bresch\uc2  commented: "Mylan's immediate launch of the first generic Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and the company's simultaneous launch of Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base), further demonstrates our commitment to continue expanding access to high quality medicines for patients who need them in the U.S. and around the world. We look forward to continue growing our portfolio of more than 1,100 generic pharmaceutical products to further support this cause."\par \par \uc2 Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), had U.S. sales of approximately $262.5 million for the 12 months ending Sept. 30, 2012, according to \uc2 IMS Health\uc2 , and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base), had U.S. sales of approximately $344.7 million for the same period. Mylan is shipping the orally disintegrating and immediate-release versions of this product immediately.\par \par \uc2 Currently, Mylan has 183 ANDAs pending FDA approval representing $79.9 billion in annual sales, according to \uc2 IMS Health\uc2 . Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $20.8 billion in annual brand sales, for the 12 months ending June 30, 2012, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020130102e9120006b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw182\pich40\picscaley100\picscalex100\picwgoal2730\pichgoal600
47
4946383961B6002800F7000095A4CE3957A34964AAD1D8EAA4B1D5677EB8C2CBE3F0F2F85871B12A4A9C8598C6E1E5F1768BBFB3BEDCF2F4F9FEFEFFEAEDF5FD
FDFEFAFAFDFCFCFDD5DBEBD0D7E9FBFCFDF9FAFCDCE1EFF3F5FAECEFF6D6DCECF4F6FAA7B4D6D3DAEBEEF0F7EFF1F8DEE3F0DADFEEE9ECF5F1F3F8F4F5FAB4BF
DCC9D1E6FBFBFDEAEDF6CFD6E9E6E9F3F8F9FCC6CEE4E4E8F2F5F6FAFEFFFFE2E7F2E3E7F2CDD4E8D3D9EBA8B4D6FAFAFCF6F8FBD3D9EAABB7D7A8B4D7E0E4F0
CED5E8EDEFF6909FCBC0C8E08F9FCBB1BCDA5C74B47488BFE2E6F2A6B3D5BBC5DFB5C0DD9EACD2DFE4F0BDC7E1BEC7E092A2CCE7EAF3B0BCDB6C81BADEE2EFA2
B0D4D9DFEE3855A3C4CDE4FAFBFDD9DEEDA4B1D4E7EAF4BAC4DECCD3E79AA9D0BFC8E1D1D8E9DEE3EFD2D9EA768ABF4561AAC2CAE2ACB8D85C73B4BEC7E1BAC4
DFAAB7D8AFBAD9EFF2F8DBE1EFBBC4DFC1CAE2BDC6E0E5E9F38294C591A1CCD4DAEBB3BEDBCDD5E8D1D7E98899C7A1AFD4F5F7FA97A7CFE8ECF58194C5DDE2EF
5A72B2E8EBF5A8B5D7E9ECF4E8EBF4F6F7FBB0BBDA8B9BC9DDE2F0A3B1D5C2CBE2E8ECF4778BC0E2E6F1CBD3E7E7EBF3DFE3F0ADB9D9E4E8F3EFF1F71B3D95FF
FFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000B60028000008FF0023091C48B0A0C18308132A5CC8B0A1C38710234A9408A9A20187042A0698C8
B1A3C78F20431AAC08E962C38C90368A5CC9B2A5CB89244D3244A9F2A5CD480048426270B367C7981835FA7C994027A40543933A047A5228C102462B1E201800
128082500714CC191552039C56093680A46061009539B52A14103500D24850A34E1D08154141B66A231D80244060D1A80206B02D2B500124047317329DE9942E
A4BC0601244090E0ADC0AC091324D81A76E058C2090D2376C83671CEAB701F273400092A01827807EEED4BF034C1038323192EF070F1429A58551F5C9000C081
04BC1D432EA899336A819F131E4060154100B50096C386641AD2EBD4DA070AFFB02BA066A4D802673B2F889B6F6B885DE3B70D4E12F465B45E9567DE5C3BBEFD
8267CD751A75C91DC49651FCA5561F675AB1061A7A7AF1B51E7B6C15B8947C18A6145C7863195513660835D7DF73914477907A0351E7DD5ADC0D94116A20B2F7
974E6A4188E240B61964D857F065289F79E01D14808526C66890883876061D5999C5371A42A5B9D899917499771C6D2A1A455B92240EB46344BE2904DC535D1D
F0E57617C5A59385480A94E392FF1164984E022CC0404A5D8AD7D65B6AEA7480895E868592515DBE29677E3D96149486363D1081406368100921492865E9A591
8499D0982F7920874004A410490B5A606AAA4F9A22C4A94B8C1C11890EA26EFFE14224205440C3A9B8B294EA41AB8A54C4061238A157173720B100076CD40081
04B9360BD2AE06F51A520D1844D041241D54104922134C0045242A5020850717386B2E98162D0A6448037C40831109B9F181030E9C6BEF858A36C56848660C11
C92015F440C7420BF0800104F7268C10B40549DBD10A2744B200060E4540020A0A679CB1082EA011057B0CCCC8805616C46005B31AA7DCEC0391E8D186410624
20C077034075D503F3AAACB3A91B4CB1422422DC41D0004ABA28C0011748BAF3D24A95B0864042A84010025B326D75B36F2CC1DE8A0A5907A0879719855496E9
12B4D34067B3A6D3BA57635A470E05B116DED4E62DA0644E0205C053615A79FFDDDFD9670B9436D71959D6F6A5402012C92261583090DC0BF92D90DDCFE11D09
D98A66F95D418167CA93DA24B17DF85076C011C90B3FDC866842924B7C37247A3160D98AAD8FB4B7E791B0B6F9E8B9B640864108D8D5B5519154B576DE465D84
F9EEE719F59AEEBC3BFB872010943174D1A01E1D89041847EF3D474D141209203EC4CD974903507795237B64F0FDFB117900C603384C60909D3A8D2C50062070
00FFFF0F79001FBC6008133424062180000B00C8C085C0E005919801051612087AD5AB81184408049E00032A9C81057838880D2221030AC4010B8ECBA00A0712
817AC9600313984315D2A084481CA20F9130C10C46E0BE15FAB0200EB842243A1AC1840B28220F6A3801112211821D4CF087508CC423AE45822F9460017E8884
06C4C0059645F18B03C9C245381004818CE051604CA31A5B1210003B}}
\par\par \b \uc2 FSS  \highlight22\uc2 Launches \highlight\uc2  Stent Delivery Technology with the CE Marking of its Reconstrainable FlexStent Femoropopliteal SE Stent System\b0\par\par\uc2 303 \uc2 words\par \uc2 2 January 2013\par \uc2 Health & Beauty Close-Up\par \uc2 HEALBE\par \uc2 English\par \uc2 (c) 2013. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Flexible Stenting Solutions, Inc\uc2 . ("FSS"), a developer of next-generation peripheral, neurovascular and biliary stents, announced that it is now authorized to CE Mark and market its 6 Fr Reconstrainable FlexStent Self-Expanding Stent System in the \uc2 European Union\uc2 .\par \par \uc2 According to a release, this \b \highlight22\uc2 new device\b0 \highlight\uc2  combines the advanced FlexStent technology with unique reconstrainable stent delivery technology.\par \par \uc2 Reconstrainability enables the physician to fully recapture then reposition a partially deployed stent. Based on ongoing market research and physician feedback, FSS believes reconstrainability will be a tool for optimizing stent placement in challenging vascular anatomies thereby enhancing overall patient safety. The Reconstrainable FlexStent Femoropopliteal Self Expanding Stent System is indicated for the treatment of symptomatic atherosclerotic disease of the femoropopliteal arteries. Stent and system sizes include stent diameters of 5, 6, 7, and 8 mm in lengths of 30 to 200 mm with delivery system lengths of 80 cm and 120 cm, as originally CE Mark authorized with the standard delivery system.\par \par \uc2 FSS intends to apply this novel reconstrainable delivery technology across its platform of current and future stent products. With the elegant and user-friendly reconstrainable delivery system, the complete FlexStent family of stents can be delivered with the same simplicity and low force demonstrated by the standard delivery system. Recapture and secondary deployment of the stent in the reconstrainable system are both accomplished with equal ease and simplicity.\par \par \uc2 Janet Burpee, FSS's CEO, commented, "Our engineers and Chief Operating Officer, Bradley Beach, have exceeded my expectations in creating this novel delivery system." She further stated that "FSS is always patient focused; we are very excited about this advanced safety feature."\par \par \uc2 More Information:\par \par \uc2 flexiblestent.com\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document HEALBE0020130102e91200001\par }\par \b \uc2 Search Summary: gizem2\b0\par \par  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Text\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 ns=C22 and (hlp=((new device or new devices or new drug or new drugs or new product or new products) and (announced the launch or announces the launch or launch or launches or launched or announced new or announces new or announces launch or introduce or introduces or introduced)) or ns=(CDINN or CGVFIL)) and in=(I257 or I372) and fmt=article and date from 01/01/2013 to 12/31/2016 and roo=USA and re=USA and la=en not (ns=(CMARKR or c01 or CIPROF or C41 or C18 or C133 or NRMF or NNAM or NOBT or NLIST or NHOC or C1521 or NAMT) or in=IDDTECH or Drug Administration announced approval)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Date\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Dates\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Source\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 Not US Food and Drug Administration News (Abstracts)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Author\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Authors\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Company\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2  Not U.S. Food and Drug Administration\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Subject\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Subjects\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Industry\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Industries\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Region\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 United States Not China Not Japan Not Europe\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Language\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 English\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Results Found\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 1,392\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Timestamp\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 30 April 2019 15:14\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row }\par }}